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57 ABSTRACT 
The present invention involves water soluble hydroxy-sub 
stituted texaphyrins retaining lipophilicity, the synthesis of 
such compounds and their uses. These expanded porphyrin 
like macrocycles are efficient chelators of divalent and 
trivalent metal ions. Various metal (e.g., transition, main 
group, and lanthanide) complexes of the hydroxy-substi 
tuted texaphyrin derivatives of the present invention have 
unusual water solubility and stability. They absorb light 
strongly in a physiologically important region (i.e. 690-880 
nm). They have enhanced relaxivity and therefore are useful 
in magnetic resonance imaging. They form long-lived triplet 
states in high yield and act as photosensitizers for the 
generation of singlet oxygen. Thus, they are useful for 
inactivation or destruction of enveloped viruses, mono 
nuclear or other cells infected with such viruses as well as 
tumor cells. They are water soluble, yet they retain sufficient 
lipophilicity so as to have greater affinity for lipid rich areas 
such as atheroma and tumors. They may be used for mag 
netic resonance imaging followed by photodynamic tumor 
therapy in the treatment of atheroma and tumors. These 
properties, coupled with their high chemical stability and 
appreciable solubility in water, add to their usefulness. 
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WATER SOLUBLE TEXAPHYRN METAL 
COMPLEX PREPARATION 
The government has certain rights in the present inven 
tion pursuant to National Institutes of Health contract 
AI28845. 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a divisional application of Ser. No. 
07/822,964, filed Jan. 21, 1992 now U.S. Pat. No. 5,252,720. 
Ser. No. 07/822,964 is a continuation-in-part of U.S. Ser. 
No. 771,393 filed Sep. 30, 1991 now abandoned which is a 
continuation-in part of U.S. Ser. No. 539,975 filed Jun. 18, 
1990 (since issued as U.S. Pat. No. 5,162,509, Nov. 10, 
1992) which is a division of U.S. Ser. No. 320,293 filed Mar. 
6, 1989 (since issued as U.S. Pat. No. 4,935,498, Jun. 19, 
1990)and is a continuation of international application no. 
PCT/US90/01208, internationally filed 6 March, 1990, all of 
which are incorporated by reference herein. 
BACKGROUND OF THE INVENTION 
The porphyrins and related tetrapyrrole macrocycles are 
among the most versatile of tetradentate ligands'. Attempts 
to stabilize higher coordination geometries with larger por 
phyrin-like aromatic macrocycles have met with little suc 
cess. Only the uranyl complex of "superphthalocyanine” 
has been isolated and characterized structurally,” although 
several other large porphyrin-like aromatic macrocycles, 
including the "sapphyrins", "oxosapphyrins", 
"platyrins”, “pentaphyrin", and "26porphyrin',' have 
been prepared in their metal free forms. Large, or 
"expanded” porphyrin-like systems are of interest for sev 
eral reasons: They could serve as aromatic analogues of the 
better studied porphyrins' or serve as biomimetic models 
for these or other naturally occurring pyrrole-containing 
systems.' In addition, large pyrrole containing systems 
offer possibilities as novel metal binding macrocycles.' 
13b,35,14 For instance, suitably designed systems could act as 
versatile ligands capable of binding larger metal cations 
and/or stabilizing higher coordination geometries' than 
those routinely accommodated within the normally tetraden 
tate ca. 2.0 A radius porphyrin core.' The resulting com 
plexes could have important application in the area of heavy 
metal chelation therapy, serve as contrast agents for mag 
netic resonance imaging (MRI) applications, act as vehicles 
for radioimmunological labeling work, or serve as new 
systems for extending the range and scope of coordination 
chemistry.' In addition, the free-base (metal-free) and/or 
diamagnetic metal-containing materials could serve as use 
ful photosensitizers for photodynamic therapeutic applica 
tions. In recent years a number of pentadentate polypyrrolic 
aromatic systems, including the "sapphyrins", "oxosap 
phyrins", "smaragdyrins", "platyrins", and "pentaphy 
rin' have been prepared and studied as their metal-free 
forms. For the most part, however, little or no information is 
available for the corresponding metallated forms. Prior to 
this invention the uranyl complex of "superphthalocyanine' 
was the only metal-containing pentapyrrolic system which 
has been prepared and characterized structurally. The 
"superphthalocyanine' system is not capable of existence in 
either its free-base or other metal-containing forms. Thus, 
prior to the present invention, no versatile, structurally 
characterized, pentadentate aromatic ligands were available, 












pentadentate systems had previously been reported.'' 
Gadolinium(III) complexes derived from strongly binding 
anionic ligands, such as diethylenetriamine pentaacetic acid 
(DTPA),'' 1,4,7,10-tetraazacyclododecane N,N',N',N"- 
tetraacetic acid (DOTA),' and 1,10-diaza-4,7,13,16 
tetraoxacyclooctadecane-N,N'-diacetic acid (dacda),' are 
among the most promising of the paramagnetic contrast 
agents currently being developed for use in magnetic reso 
nance imaging (MRI)''The complex, (GdCDTPA), is now 
being used clinically in the United States in certain enhanced 
tumor detection and other imaging protocols.' Nonetheless, 
the synthesis of other gadolinium(III) complexes remains of 
interest since such systems might have greater kinetic sta 
bility, superior relaxivity, or better biodistribution properties 
than this or other carboxylate-based contrast agents. The 
water-soluble porphyrin derivatives, such as tetrakis (4-sul 
fonatophenyl) porphyrin (TPPS) cannot accommodate com 
pletely the large gadolinium(III) cation' within the rela 
tively small porphyrin binding core (rs2.0 A"), and, as a 
consequence, gadolinium porphyrin complexes are invari 
ably hydrolyrically unstable.' Larger porphyrin 
like ligands may offer a means of circumventing this prob 
em.51-59 
A promising new modality for use in the control and 
treatment of tumors is photodynamic therapy (PDT).'' 
This technique uses of a photosensitizing dye, which local 
izes at, or near, the tumor site, and when irradiated in the 
presence of oxygen serves to produce cytotoxic materials, 
such as singlet oxygen (O,(A)), from benign precursors 
(e.g. (O,(2)). Diamagnetic porphyrins and their deriva 
tives are the dyes of choice for PDT. It has been known for 
decades that porphyrins, such as hematoporphyrin, localize 
selectively in rapidly growing tissues including sarcomas 
and carcinomas.' The hematoporphyrin derivative (HPD), 
''''' is an incompletely characterized mixture of mono 
meric and oligomeric porphyrins.' The oligomeric spe 
cies, which are believed to have the best tumor-localizing 
ability,' are marketed under the trade name Photofrin IIG) 
(PII) and are currently undergoing phase III clinical trials for 
obstructed endobronchial tumors and superficial bladder 
tumors. The mechanism of action is thought to be the 
photoproduction of singlet oxygen (O,(A)), although 
involvement of superoxide anion or hydroxyl and/or por 
phyrin-based radicals cannot be entirely ruled out.' 
Promising as HPD is, it and other available photosensitizers 
(e.g., the phthalocyanines and naphthalocyanines) suffer 
from serious disadvantages. 
While porphyrin derivatives have high triplet yields and 
long triplet lifetimes (and consequently transfer excitation 
energy efficiently to triplet oxygen),' their absorption in 
the Q-band region parallels that of heme-containing tissues. 
Phthalocyanines and naphthalocyanines absorb in a more 
convenient spectral range but have significantly lower triplet 
yields;' moreover, they tend to be quite insoluble in polar 
protic solvents, and are difficult to functionalize. Thus the 
development of more effective photochemotherapeutic 
agents requires the synthesis of compounds which absorb in 
the spectral region where living tissues are relatively trans 
parent (i.e., 700-1000 nm),' have high triplet quantum 
yields, and are minimally toxic. The present inventors have 
recently reported' (see Example 1) the synthesis of a new 
class of aromatic porphyrin-like macrocycles, the tripyr 
roledimethine-derived "texaphyrins', which absorb strongly 
in the tissue-transparent 730-770 nm range. The photo 
physical properties of metallotexaphyrins parallel those of 
the corresponding metalloporphyrins and the diamagnetic 




Acquired immunodeficiency syndrome (AIDS) is among 
the most serious public health problems facing our nation 
today. AIDS, first reported in 1981 as occurring among male 
homosexuals,' is a fatal human disease which has now 
reached pandemic proportions. At present, sexual relations 
and needle-sharing are the dominant mechanisms for the 
spread of AIDS." Since the testing of blood supplies began, 
the percentage of AIDS infections due to blood transfusions 
has dropped considerably.60,104-107 However, an abso 
lutely fail-proof means must be developed to insure that all 
stored blood samples are free of the AIDS virus (and ideally 
all other blood-borne pathogens). Serologic tests for HIV-1 
are insufficient to detect all infected blood samples, in 
particular, those derived from donors who have contracted 
the disease but not yet produced detectable antibodies.' 
107 
Any blood purification procedure used to remove AIDS 
virus or other blood-borne pathogens should operate without 
introducing undesirable toxins, damaging normal blood 
components, or inducing the formation of harmful metabo 
lites. This precludes the use of common antiviral systems 
such as those based on heating, UV irradiation, or purely 
chemical means. A promising approach is the photodynamic 
one alluded to above. Here, preliminary studies, carried out 
by researchers at the Baylor Research Foundation, Dr. 
Matthews and his team,' and others,' have served to 
show that HPD and PII, in far lower dosages than are 
required for tumor treatment, act as efficient photosensitizers 
for the photo-deactivation of cell-free HIV-1, herpes simplex 
(HSV), hepatitis and other enveloped viruses. The success of 
this procedure derives from the fact that these dyes localize 
selectively at or near the morphologically characteristic, and 
physiologically essential, viral membrane ("envelope”) and 
catalyze the formation of singlet oxygen upon photoirradia 
tion. The singlet oxygen destroys the essential membrane 
envelope. This kills the virus and eliminates infectivity. 
Photodynamic blood purification procedures, therefore, rely 
on the use of photosensitizers which localize selectively at 
viral membranes, just as more classic tumor treatments 
require dyes that are absorbed or retained preferentially at 
tumor sites. Simple enveloped DNA viruses like HSV-1 are 
good models for testing putative photosensitizers for poten 
tial use in killing the far more hazardous HIV-1 retrovirus. 
This correspondence holds only as far as freely circulating 
(as opposed to intracellular) viruses are concerned. Com 
plete prophylactic removal of HIV-1 from blood products 
will require the destructive removal of the virus from within 
monocytes and T lymphocytes.' 
This "first generation' of dyes suffers from a number of 
serious deficiencies which may militate against their even 
tual use in biomedical applications. Each of these deficien 
cies has important clinical consequences. Since HPD and PII 
do not contain a single chemically well-defined constituent, 
coupled with the fact that the active components have yet to 
be identified with certainty,' means that the effective 
concentrations vary from preparation to preparation. Thus 
the dosage, and the light fluence, cannot be optimized and 
predetermined for any particular application. Since they are 
not metabolized rapidly, significant quantities of these dyes 
remain in stored blood units after prophylactic photoinduced 
HIV-1 removal and remain in patients bodies long after 
photodynamic tumor treatment. The latter retention prob 
lem, in particular, is known to be serious; HPD and PII 
localize in the skin and induce photosensitivity in patients 
for weeks after administration.64,109 Since the longest 
wavelength absorption maximum for these dyes falls at 630 












dispersed or attenuated before reaching the center of a 
deep-seated tumor and as a result, little of the initial light is 
available for singlet oxygen production and therapy.''' A 
study using a mouse model with a 3 mm tumor implanted 
beneath the skin indicated that as much as 90% of the energy 
is lost by the base of the tumor.' More effective treatment 
of deep-seated or large tumors may be possible if photosen 
sitizers could be developed which absorb in the >700 nm 
region, provided, of course, they retain the desirable features 
of HPD and PII (e.g. selective localization in target tissues 
and low dark toxicity). One aspect of the present invention 
involves development of such improved photosensitizers for 
use in photodynamic tumor treatment and blood purification 
protocols. 
The following list summarizes features which would be 
desirable in biomedical photosensitizers: 
1. Easily available 
2. Low intrinsic toxicity 
3. Long wavelength absorption 
4. Efficient photosensitizer for singlet oxygen production 
5 Fair solubility in water 
6. Selective up-take in tumor tissue and/or 
7. Showing high affinity for enveloped viruses 
8. Quick degradation and/or elimination after use 
9. Chemically pure and stable 
10. Easily subject to synthetic modification 
In recent years, considerable effort has been devoted to 
the synthesis and study of new photosensitizers which might 
meet these desiderata. Although a few of these have con 
sisted of classic dyes such as those of the rhodemine and 
cyanine classes,' many have been porphyrin deriva 
tives with extended it networks.'''Included in this latter 
category are the purpurins and verdins' of Morgan and 
other chlorophyll-like species,' 'the benz-fused porphy 
rins of Dolphin etel,' and the sulfonated phthalocyanines 
and napthophthalocyanines studied by Ben-Hur,' Rodg 
ers,' and others.''' Of these, only the napthophthalo 
cyanines absorb efficiently in the most desirable >700 mm 
spectral region. These particular dyes are difficult to prepare 
in a chemically pure, water soluble form and are relatively 
inefficient photosensitizers for singlet oxygen production, 
perhaps even acting photodynamically via other oxygen 
derived toxins (e.g. superoxide). Thus a search continues for 
yet a "third generation' of photosensitizers which might 
better meet the ten critical criteria listed above. 
It is an important aspect of the present invention that an 
improved "third generation” of photosensitizers is obtained 
using large, pyrrole-containing "expanded porphyrins'. 
These systems, being completely synthetic, can be tuned so 
as to incorporate any desired properties. In marked contrast 
to the literature of the porphyrins, and related tetrapyrrolic 
systems (e.g. phthalocyanines, chlorins, etc.), there are only 
a few reports of larger pyrrole-containing systems, and only 
a few of these meet the criterion of aromaticity deemed 
essential for long-wavelength absorption and singlet oxygen 
photosensitization.' In addition to the present inventors' 
studies of texaphyrin 1' (see FIGS. 1B and 2B), and 
"sapphyrin', first produced by the groups of Woodward and 
Johnson, there appear to be only three large porphyrin-like 
systems which might have utility as photosensitizers These 
are the "platyrins" of LeGoff, the stretched porphycenes of 
Vogel' and the vinylogous porphyrins of Franck.' The 
present studies indicate that an expanded porphyrin 
approach to photodynamic therapy is promising. The por 
phycenes,' 'a novel class of "contracted porphyrins” 
also show promise as potential photosensitizers.' 
5,569,759 
S 
The present invention involves a major breakthrough in 
the area of ligand design and synthesis. It involves the 
synthesis of the first rationally designed aromatic pentaden 
tate macrocyclic ligand, the tripyrroledimethine-derived 
"expanded porphyrin" 1.' This compound, to which the 
trivial name "texaphyrin' has been assigned, is capable of 
existing in both its free-base form and of supporting the 
formation of hydrolyrically stable 1:1 complexes with a 
variety of metal cations, such as Cd'", Hg”, In", Y", 
Nd", Eu", Sm", La", Lu", Gd, and other cations of the 
lanthanide series that are too large to be accommodated in a 
stable fashion within the 20% smaller tetradentate binding 
core of the well-studied porphyrins. In addition, since the 
free-base form of 1 is a monoanionic ligand, the texaphyrin 
complexes formed from divalent and trivalent metal cations 
remain positively charged at neutral pH. As a result, many 
of these complexes are more water soluble than the analo 
gous porphyrin complexes. 
To date, two X-ray crystal structures of two different Cd' 
adducts. have been obtained, one of the coordinatively satu 
rated, pentagonal bipyramidal bispyridine complex;''' the 
other of a coordinatively unsaturated pentagonal pyramidal 
benzimidazole complex.' Both confirm the planar penta 
dentate structure of this new ligand system and support the 
assignment of this prototypical "expanded porphyrin' as 
aromatic. 
Further support for the aromatic formulation comes from 
the optical properties of 1 and 1. The lowest energy 
Q-type band of the structurally characterized bispyridine 
cadmium(II) adduct of complex I at 767 nm (e= 51,900) in 
CHCl is 10-fold more intense and red shifted by almost 200 
nm as compared to that of a typical reference cadmium(II) 
porphyrin. Compound 1 and both its zinc.(II) and cad 
mium(II) complexes are very effective photosensitizers for 
singlet oxygen, giving quantum yields for 'O, formation of 
between 60 and 70% when irradiated at 354 nm in air 
saturated methanol.' Related congeneric texaphyrin sys 
tems bearing substituents on the tripyrrole and/or phenyl 
portions and incorporating La(III) and/or Lu(III) metal cen 
ters, have been found to produce 'O, in quantum yields 
exceeding 70% when irradiated under similar conditions. 
Thus, it is this remarkable combination of light absorbing 
and O, photosensitizing properties which make these sys 
tems ideal candidates for use in photodynamic therapy and 
blood purification protocols. 
SUMMARY OF THE INVENTION 
The texaphyrin derivatives described in this continuation 
in-part application are extensions of the structure 29 in 
FIG. 27 of the parent application Ser. No. 771,393. By 
texaphyrin, we mean a compound with the central ring 
system depicted in structure 1A. 
The present invention involves hydroxyl derivatives of 
texaphyrin, a novel tripyrrole dimethine-derived "expanded 
porphyrin', the synthesis of such compounds and their uses. 
The desirable properties of hydroxylated derivatives of 
texaphyrin are: 
1) appreciable solubility, particularly in aqueous media; 
2) biolocalization in desired target tissue; 
3) the ability to attach to solid matrices; 
4) the ability to be attached to biomolecules; 
5) efficient chelation of divalent and trivalent metal cat 
10ns, 
6) absorption of light in the physiologically important 













7) high chemical stability; 
8) ability to stabilize diamagnetic complexes that form 
long-lived triplet states in high yield and that act as 
efficient photosensitizers for the formation of singlet 
OXygen. 
The reduced spform of the texaphyrin molecule has the 
structure 1A shown in FIG. A. Upon oxidation, an aromatic 
structure 1 is formed and upon incorporation of a metal salt, 
such as CdCl2, the chelate 1 or its analogue incorporating 
other di- or trivalent cations, is formed. The synthetic 
scheme for the basic texaphyrin molecule is described in 
FIGS. 2A and 2B. These molecules are the subject of 
previous patent applications Ser. Nos. 771,393 and 539,975. 
The derivatives disclosed in this invention have substituents 
on the benzene ring portion of the molecule referred to as B 
or the tripyrrole portion of the molecule referred to as T. The 
number following the B or T indicates the number of 
hydroxyl groups that have been incorporated into that por 
tion of the molecule. 
The present invention relates to water soluble compounds 
retaining lipophilicity and having the structure: 
Rs 
R5 
wherein M is H, a divalent or a trivalent metal cation; 
wherein N is an integer between -20 and +2; and 




alkyl groups attached via a carbon or oxygen; 
hydroxyalkyl groups attached via a carbon or oxygen; 
these may be C.H2O, or OC, H2O, where at 
least one of the subtituents R, R2, R, R, and R has 
at least one hydroxy substituent; where the molecular 
weight of any one of R, R2, R, R or Rs is less than 
or equal to about 1000 daltons; where n is a positive 
integer or Zero; and 
where y is zero or a positive integer less than or equal to 
(2n+1); 
oxyhydroxyalkyl groups (containing independently 
hydroxy substituents or ether branches) attached via a 
carbon or oxygen; these may be Co-Ho-2O,O, 
or OCo-Ho-1 O,O, where n is a positive inte 
ger or zero, x is Zero or a positive integer less than or 
equal to n, and y is zero or a positive integer less than 
or equal to (2n+1)-2x; 
oxyhydroxyalkyl groups (containing independently sub 
stituents on the hydroxyls of the oxyhydroxyalkyl 
compounds described above or carboxyl derivatives) 
attached via a carbon or oxygen; these may be CH 




(CH2)COR"; where n is a positive integer or zero, y 
is zero or a positive integer less than (2n+1)-q), q is 
zero or a positive integer less than or equal to 2n+1, R 
is independently H, alkyl, hydroxyalkyl, saccharide, 
Con-whi (2n-1 –2wOwO. OCCH (2n+1)-2w) O.O. 
or N(R)OCCH2--1-2O.O., where m is a posi 
tive integer or zero,w is zero or a positive integer less 
than or equal to n, z is zero or a positive integer less 
than or equal to (2m+1)-2w), R is H, alkyl, hydroxy 
alkyl, or C.Hon. --O.R. where m is a positive 
integer or zero, Z is zero or a positive integer less than 
(2m+1)-r), r is zero or a positive integer less than or 
equal to 2m+1, and R is independently H, alkyl, 
hydroxyalkyl, or saccharide; 
carboxyamidealkyl groups (containing independently 
hydroxyl groups, or secondary or tertiary amide link 
ages) attached via a carbon or oxygen; these may be 
(CH2)CONHR, O(CH),CONHR 
(CH2)CON(R), or O(CH2)CONCR"); where n is a 
positive integer or zero, R is independently H, alkyl, 
hydroxyalkyl, Saccharide, Con-Hicon-1-2, O.O. 
OCCon-Hicom 1-2O.O. or N(R)OCCon-whom 
1-2wOO, where m is a positive integer or zero, w is 
zero or a positive integer less than or equal to m, Z is 
zero or a positive integer less than or equal to (2m+ 
1)-2w), R is H, alkyl, hydroxyalkyl, or CH2 
OR; where m is a positiveinteger or zero, Z is zero or 
a positive integer less than (2m+1)-r), r is zero or a 
positive integer less than or equal to 2m+1, and R is 
independently H, alkyl, hydroxyalkyl, or saccharide; or 
carboxyalkyl groups (containing independently hydroxyl 
groups, carboxyl substituted ethers, amide substituted 
ethers or tertiary amides removed from the ether) 
attached via a carbon or oxygen; these may be CH 
(2n+1)-al.O.R. Or OCH2,+1)-a0,R, where n is a 
positive integer or zero, y is zero or a positive integer 
less than (2n+1)-q), q is zero or a positive integer less 
than or equal to 2n+1, R is (CH2)CO,R, 
(CH2)CONHR or (CH2)CON(R); where n is a 
positive integer or zero, R is independently H, alkyl, 
hydroxyalkyl, saccharide, C-H2n-12 O.O., 
OCCH to 1-2O, O, or N(R)OCCnHon. 
1)-2wOO, where m is a positive integer or zero, w is 
zero or a positive integer less than or equal to m, Z is 
zero or a positive integer less than or equal to 
(2m+1)-2w), R is H, alkyl, hydroxyalkyl, or C.H. 
1)--OR', where m is a positive integer or zero, Z is 
zero or apositive integer less than (2m+1)-r, r is zero 
or a positive integer less than or equal to 2m+1, and R' 
is independently H, alkyl, hydroxyaikyl, or saccharide; 
where at least one of R, R2, R, R and Rs has at least one 
hydroxy substituent and the molecular weight of any of R, 
R,R,R or Rs is less than or equal to about 1000 daltons. 
In the above-described metallic complexes M may be a 
divalent metal ion selected from the group consisting of 
Cat?, Mn", Co"?, Ni, Zn, Cd, Hg, Sm'? and UO,', 
(and N is 1). In certain aspects M is preferably Cd' or Zn 
or Hg". When M is a trivalent metal ion, it is preferably 
selected from the group consisting of Mn, Co", Ni",Y, 
8 
Most preferred trivalent metal ions are In La", Lu", and Gd. 
A preferred water solubie compound retaining lipophilic 
ity has hydroxyl groups only in the B portion of the molecule 










In 3 Pr3 Ndl3 Smt Fe3 Ho Ce3 Eut Gd+3 Tb3 60 
Dy", Er, Tm, Yb", Lu, La and U"; (and N is 2). 
wherein M is H, a divalent or a trivalent metal cation; N 
is an integer between -20 and +2; R,R,R, and R. 
are independently CH2 where n is a positive inte 
ger, and Rs is hydroxyl, hydroxyalkyl, oxyhydroxy 
alkyl, carboxyalkyl or carboxyamidealkyl, where Rs 
has at least one hydroxy substituent, and the molecular 
weight of any one of R, R2, R., R., or Rs is less than 
or equal to about 1000 daltons. 
Another preferred water soluble compound retaining lipo 
philicity has hydroxyl groups only in the T portion of the 
molecule and has the structure: 
wherein M is H, a divalent or a trivalent metal cation; N 
is an integer between -20 and +2; R, R2, R., and R. 
are independently hydroxyl, alkyl, hydroxyalkyl, oxy 
hydroxyalkyl, carboxyalkyl or carboxyamidealkyl; and 
Rs is H or CH2, where at least one of R, R2, R3, 
and Ra has at least one hydroxy substituent, the 
molecular weight of any one of R, R2, R., R., or Rs 
is less than or equal to about 1000 daltons, and n is a 
positive integer. 
Another preferred water soluble compound retaining lipo 
philicity has hydroxyl groups in both the B and T portions 




wherein M is H, a divalent or a trivalent metal cation; N 
is an integer between -20 and +2; R, R2, R, Ra, and 
Rs are independently H, OH, C, H2O, or OCH2 
1O, where at least one of R, R2, Ra, and Ra has at 
least one hydroxy substituent, R has at least one 
hydroxy substituent, the molecular weight of any one 
of R, R., R., R., or Rs is less than or equal to about 
1000 daltons, n is a positive integer or zero, and y is 
Zero or a positive integer less than or equal to (2n+1). 
In the above described metallic complexes M may be a 
divalent metallic cation selected from the group consisting 
of Ca?, Mn2, Co, Ni, Zn, Cd?, Hg, Sm' and 
UO,', and N is 1. When M is a trivalent metal cation, it is 
preferably selected from the group consisting of Mn", Co, 
Ni3, Y-3, Int, Pr'3, Nd, Sm3, Eu3, Gd, Tb3, Dy", 
Er", Fe", Ho, Ce, Tm, Yb, Lu, La and U; and 
N is 2. Most preferred trivalent metal ions are In', Gd3, 
La", or Lu' and N is +2. 
A preferred water soluble compound retaining lipophilic 
ity of this invention has been prepared as one having the 
structure with the trivial name B2 (See FIG. 6): 
wherein M is H, a divalent or trivalent metal cation, and N 
is 0, 1 or 2. Particularly preferred metal cations are Gd, 










Another preferred water soluble compound retaining lipo 
philicity has the structure with the trivial name T2: 
-N- OH 
OH 
wherein M is H, a divalent or trivalent metal cation, and N 
is 0, 1 or 2. Particularly preferred metal cations are Gd", 
Lu, La", or In", and N is 2. 
Another preferred water soluble compound retaining lipo 





wherein M is H, a divalent or trivalent metal cation, and N 
is 0, 1 or 2. Particularly preferred metal cations are Gd", 






Another preferred water soluble compound retaining ipo 







wherein M is H, a divalent or trivalent metal cation, and N 
is 0, 1 or 2. Particularly preferred metal cations are Gd", 
Lu", La", In", and N is 2. 25 
Another preferred water soluble compound retaining lipo 








wherein M is H, a divalent or trivalent metal cation, and N 
is 0, 1 or 2. Particularly preferred metal cations are Gd', 
Lu, La, In, and N is 2. 
Another preferred water soluble compound retaining lipo 






wherein M is H, a divalent or trivalent metal cation, and N 
is 0, 1 or 2. Particularly preferred metal cations are Gd", 
Lu, La, In, and N is 2. 
In the above described preferred compounds M may be a 
divalent metallic cation selected from the group consisting 
of Ca, Mn, Co, Ni, Zn, Cd, Hg, Sm"? and 
UO', and N is 1. When M is a trivalent metal cation, it is 
preferably selected from the groug consisting of Mn", Co, 
Nit, Y+ Int3, Pr", Nd", Sm Eu", Gd", Tb3, Dy", 
Ert, Fe", Ho", Cet, Tm, Yb, Lu", La", and U"; 
and N is 2. Most preferred trivalent metal ions are In", 
Gd", La", or Lu' and N is +2. 
By combining various substituted intermediates, one 
skilled in the art can see how a large variety of hydroxy 
substituted texaphyrins could be synthesized. Water soluble 
means soluble in aqueous fluids to about 1 mM or better. 
Retaining lipophilicity means having greater affinity for 
lipid rich tissues or materials than surrounding nonlipid rich 
tissues or materials and in the case of viruses in suspension 
means affinity for the membraneous coat of the virus. Lipid 
rich means having a greater amount of triglyceride, choles 
terol, fatty acids or the like. Hydroxyalkyl means alkyl 
groups having hydroxyl groups attached. Oxyalkyl means 
alkyl groups attached to an oxygen. Oxyhydroxyalkyl means 
alkyl groups having ether oresterlinkages, hydroxyl groups, 
substituted hydroxyl groups, carboxyl groups, substituted 
carboxyl groups or the like. Saccharide includes oxidized, 
reduced or substituted saccharide. Carboxyamidealkyl 
means alkyl groups with hydroxyl groups, secondary or 
tertiary amide linkages or the like. Carboxyalkyl means 
alkyl groups having hydroxyl groups, carboxyl or amide 
substituted ethers, ester linkages, tertiary amide linkages 
removed from the ether or the like. 
A method for the synthesis of an aromatic pentadentate 
expanded porphyrin analog metal complex having at least 
one hydroxy substituent is an aspect of the present invention. 
By aromatic pentadentate expanded porphyrin analog we 
mean texaphyrin. This method comprises synthesizing a 
diformyltripyrrole having structure A, condensing said 




where R, R2, R., R., and Rs are independently H, OH, 
alkyl, oxyalkyl, hydroxyalkyl, carboxyalkyl, carboxyamid 
ealkyl or oxyhydroxyalkyl and where at least one of R, R2, 
R3, Ra, and Rs has at least one hydroxy substituent and 
where the molecular weight of any one of R, R2, R., R., or 
Rs is less than or equal to about 1000 daltons; and oxidizing 
the condensation product to form an aromatic pentadentate 
expanded porphyrin analog metal complex having at least 
one hydroxy substituent. A preferred diformyltripyrrole is 
2,5-bis (5-formyl-3-hydroxyalkyl- 4-alkylpyrrol-2-yl)m- 
ethyl-3,4-dialkylpyrrole or 2,5-bis(5-formyl-3-hydrox 
ypropyl-4-methylpyrrol-2-yl)methyl- 3,4-diethylpyrrole, 
(7, FIG. 7B); or 2,5-bis( (3-ethyl-5-formyl- 4-methylpyr 
rol-2-yl)methyl)-3,4-diethylpyrrole (6 FIG. 6). 
A preferred "B" portion of these molecules is synthesized 












droxyalkyl)benzene or 1,2-diamino-4,5-bis((3'-hydroxypro 
pyl)oxy)benzene, (6 FIG. 6), or 1,2-diamino-4,5-bis((2,3- 
dihydroxypropyl)oxy)benzene, (8 FIG. 8). 
Said condensation product is mixed in an organic solvent 
with a trivalent metal salt, a Bronsted base and an oxidant, 
and stirred at ambient temperature or heated at reflux for at 
least 2-24 hours to form an aromatic pentadentate expanded 
porphyrin analog metal complex having at least one hydroxy 
substituent. A preferred Bronsted base is triethylamine; 
preferred oxidants are air, oxygen, platinum oxide, and 
2,3-dichloro-5,6-dicyano- 1,4-benzoquinone and preferred 
organic solvents are methanol and chloroform or methanol 
and benzene. 
The metal complexes may be associated with, depending 
on the metal, anywhere from 0-6 apical ligands about the 
encapsulated metal center. The ligands are typically some 
combination of acetate, chloride, nitrate, hydroxide, water, 
or methanol and when bound, are not readily dissociable. 
The present invention involves a method of deactivating 
retroviruses and enveloped viruses in an aqueous fluid. 
Aqueous fluid may be biological fluids, blood, plasma, 
edema tissue fluids, ex vivo fluids for injection into body 
cavities, cell culture media, supernatant solutions from cell 
cultures and the like. This method comprises adding a water 
Soluble hydroxy-substituted aromatic pentadentate 
expanded porphyrin analog metal complex retaining lipo 
philicity to said aqueous fluid and exposing the mixture to 
light to effect the formation of singlet oxygen. Preferred 
metals are diamagnetic metals and a preferred metal con 
plex is the Lu, La or In complex of B2T2. 
A method of light-induced singlet oxygen production is an 
aspect of the present invention. The method comprises the 
use of a water soluble hydroxy-substituted aromatic penta 
dentate expanded porphyrin analog metal complex retaining 
lipophilicity and having intrinsic biolocalization selectivity 
as a photosensitizer. Preferred metals are diamagnetic metals 
and a preferred metal complex is the Lu, La or In complex 
of B2T2. Intrinsic biolocalization selectivity means having 
an inherently greater affinity for certain tissues relative to 
Surrounding tissues. 
A method of enhancement of relaxivity comprising the 
administration of a paramagnetic metal ion (such as gado 
linium, for example) complexed with a water soluble 
hydroxy-substituted aromatic pentadentate expanded por 
phyrin analog retaining lipophilicity is an aspect of the 
present invention. A preferred complex is the Gd complex of 
B2T2. 
A method of treating a host harboring atheroma or benign 
or malignant tumor cells is an aspect of the present inven 
tion. The method comprises the administration to a host as 
a first agent, a water soluble hydroxy-substituted aromatic 
pentadentate expanded porphyrin analog-detectable-metal 
complex retaining lipophilicity, said complex exhibiting 
selective biolocalization in such atheroma or tumor cells 
relative to surrounding tissue; determining localization sites 
in the host by reference to such detectable metal, followed 
by the administration to the host as a second agent a water 
soluble hydroxy-substituted aromatic pentadentate 
expanded porphyrin analog-detectable-metal complex 
retaining lipophilicity and having essentially identical biolo 
calization property and exhibiting the ability to generate 
singlet oxygen upon exposure to light; and photoirradiating 
the second agent in proximity to said atheroma or tumor 
cells. The first agent is further defined as being a paramag 
netic metal complex, said paramagnetic metal serving as 
said detectable metal. In this case, the determination of 
localization sites occurs by magnetic resonance imaging and 
5,569,759 
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the second agent is a diamagnetic metal complex. The 
paramagnetic metal is most preferably Gd(III) and the 
diamagnetic metal is most preferably La(III), Lu(III) or 
In(III). A variation of this method uses as a first agent, a 
gamma emitting radioisotope as the detectable-metal con 
plex, said gamma emitting radioisotope serving as said 
detectable metal; determination of localization sites occurs 
by gamma body scanning and is followed by photoirradiat 
ing the second agent as described above. A preferred first 
agent is the Gd complex of B2T2, 4,5-diethyl-10,23-dim 
ethyl-9,24-bis( 3-hydroxypropyl)-16,17-(3-hydroxypropy 
loxy)-13.20,25,26,27-pentaaza pentacyclo[20.2.1.1.1 
11.0''']heptacosa- 1,3,5,7,9,11(27), 12,1 4(19), 15,17.20, 
22(25),23-tridecaene and a preferred second agent is the Lu, 
La or In complex of B2T2. Detectable as used herein means 
that the location may be found by localization means such as 
magnetic resonance imaging if the metal is paramagnetic or 
gammaray detection if the metal is gamma emitting or using 
monochromatic X-ray photon sources. Selective biolocal 
ization means having an inherently greater affinity for cer 
tain tissues relative to surrounding tissues. Essentially iden 
tical biolocalization property means the second agent is a 
texaphyrin derivative having about the same selective tar 
geting characteristics in tissue as demonstrated by the first 
agent. 
Another aspect of this invention is a method of imaging 
atheroma in a host comprising the administration to the host 
as an agent a water soluble hydroxy-substituted aromatic 
pentadentate expanded porphyrin analog-detectable-metal 
complex retaining lipophilicity, said complex exhibiting 
selective biolocalization in such atheroma, and imaging the 
atheroma in the host by reference to such detectable metal. 
The agent is preferably a water soluble hydroxy-substituted 
aromatic pentadentate expanded porphyrin analog-paramag 
netic metal complex retaining lipophilicity, said paramag 
netic metal serving as said detectable metal; amd imaging of 
the atheroma occurs by magnetic resonance imaging. The 
paramagnetic metal is preferably Gd(III). The agent is 
preferably the Gd complex of B2T2, 4,5-diethyl-10,23 
dimethyl-9,24-bis(3-hydroxypropyl)-16,17-(3-hydroxypro 
pyloxy)-13,20,25,26,27-pentaaza pentacyclo[20.2.1.1.1 
11.0''']heptacosa- 1,3,5,7,9,11(27),12,1 4(19), 15,17.20, 
22(25),23-tridecaene. 
In these methods of use, by water soluble hydroxy 
substituted aromatic pentadentate expanded porphyrin ana 
log retaining lipophilicity we mean water soluble texaphy 
rins retaining lipophilicity, however, one skilled in the art 
would recognize that water soluble hydroxy substituted 
sapphyrin metal complexes may be used in methods for 
generating singlet oxygen. Sapphyrins compounds are dis 
closed in patent applications Ser. No. 454.298 and 454,301 
which are incorporated by reference herein. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 1A and 1B shows a schematic representation of the 
reduced (1) and oxidized (1) forms of the free-base 
"texaphyrin' and a representative five coordinate cadmium 
complex (1) derived from this "expanded porphyrin'. 
FIGS. 2A and 2B schematically summarizes the synthesis 
of texaphyrin (2 also designated 1 in FIG. 1B). 
FIGS. 3A and 3B shows "H NMR spectrum of 1.NO in 
CDC. The signals at 1.5 and 7.26 ppm represent residual 
water and solvent peaks respectively. 
FIGS. 4A and 4B shows a UV-visible spectrum of 1.NO 













FIGS.5A and 5B shows metal complexes and derivatives 
(5-5) of compounds of the parent patent application. 
FIG. 6 schematically summarizes the synthesis of B2TXP, 
6 and (LuB2TXP',6, compounds of the present inven 
tion. compounds 6 and 6 are claimed as intermediates in 
the synthesis of B2TXP in the present invention. 
FIGS. 7A and 7B schematically summarizes the synthesis 
of B2T2TXP(7), (Gd B2T2 TXP?" (7), Lu B2T2 TXP)* 
(7), and La B2T2 TXP' (7), compounds of the present 
invention. Other trivalent metal complexes analogous to 
those shown can be prepared including that of InCIII). 
Compound 7 is claimed as an intermediate in the synthesis 
of B2T2TXP in the present invention. 
FIG. 8 schematically summarizes the synthesis of 
B4T2TXP (8) and (Gd B4T2 TXP” (8), compounds of 
the present invention. Compound 8 is claimed as an 
intermediate in the synthesis of B4T2TXP in the present 
invention. 
FIG. 9 shows mononuclear cell killing by complexes 
20M=Zn') and 1c without irradiation. Cell kill was 
determined by 3H]-Thy uptake after phytohemagglutinin 
(PHA) stimulation. 
FIG. 10 shows mononuciear cell killing by 1 ug/ml 
complex 1 and irradiation. Cell kill was determined by 
(H)-Thy uptake after PHA stimulation. 
FIGS. 11A, 11B and 11C summarizes the synthesis of 
polyether-linked polyhydroxylated texaphyrins. Ts is a tosyl 
group. 
FIG. 12 summarizes the synthesis of catechol (i.e. ben 
zene diol) texaphyrin derivatives bearing further hydroxy 
alkyl substituents off the tripyrrane-derived portion of the 
macrocycle. 
FIG. 13 provides an example of a saccharide substituted 
texaphyrin in which the saccharide is appended via an 
acetal-like glycosidic linkage. Triflate is trifluoromethane 
sulfonate. 
FIG. 14 summarizes the synthesis of a doubly carboxy 
lated texaphyrin system in which the carboxyl groups are 
linked to the texaphyrin core via aryl ethers or functional 
ized alkyl substituents. The products of this scheme, com 
pounds 14 and 14 could be converted on to various 
esterified products wherein the ester linkages serve to 
append further hydroxyl-containing substituents. 
FIGS. 15A and 15B summarizes the synthesis of polyhy 
droxylated texaphyrin derivatives via the use of secondary 
amide linkages. DCC is dicyclohexylcarbodiimide, DMF is 
dimethylformamide, and DME is dimethoxyethane. 
FIGS. 16A and 16B summarizes the synthesis of another 
set of polyhydroxyl substituted texaphyrin derivatives using 
similar amide bonds as in FIGS. 15A and 15B. 
FIGS. 17A and 17B summarizes the synthesis of saccha 
ride substituted texaphyrins, wherein the saccharide moi 
eties are appended via amide bonds. 
FIG. 18 summarizes the synthesis of polyhydroxylated 
texaphyrin derivatives containing branched polyhydroxyl 
(polyol) subunits appended to the texaphyrin core via aryl 
ethers. 
FIGS. 19A and 19B summarizes how similar polyol 
subunits may be appended via ester linkages. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention involves the synthesis and utility of 
novel water soluble hydroxy-substituted aromatic pentaden 
5,569,759 
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tate expanded porphyrin analog metal complexes retaining 
lipophilicity, in particular, hydroxy-substituted texaphyrin 
metal complexes. The presence in this structure of a near 
circular pentadentate binding core which is roughly 20% 
larger than that of the porphyrins, coupled with the realiza 
tion that almost identical ionic radii pertain for hexacoordi 
nate Cd' (r=0.92 A) and Gd" (re 0.94 A), prompted 
exploration of the general lanthanide binding properties of 
this monoanionic porphyrin-like ligand. The synthesis and 
characterization of a water-stable gadolinium (III) complex 
derived formally from a 16,17-dimethyl substituted ana 
logue of the original 'expanded porphyrin system is 
described, as well as the preparation and characterization of 
the corresponding europium(III) and samarium(III) com 
plexes. 
The aromatic "texaphyrin' system described herein pro 
vides an important complement to the existing rich coordi 
nation chemistry of porphyrins. For instance, by using 
methods similar to those described, zinc(II), manganese(II) 
, mercury(II), Iron(III), neodymium(III), samarium(III), 
gadolinium(III), lutetium(III), indium(III), and lanthanu 
m(III) complexes have been prepared and characterized. 
The present invention involves hydroxy substituted 
derivatives of texaphyrin, and the synthesis and character 
ization thereof. The introduction of hydroxy substituents on 
the B (benzene ring) portion of the molecule is accom 
plished by their attachment to phenylenediamine in the 4 and 
5 positions of the molecule. The introduction of hydroxy 
substituents on the T (tripyrrole) portion of the molecule is 
accomplished by appropriate functionalization of the alkyl 
substituents in the 3 and/or 4 positions of the pyrrole rings 
at a synthetic step prior to condensation with the substituted 
phenylenediamine. Most preferred derivatizations introduce 
substituents at the R and R sites of the diformyltripyrrole 
(A, pg 23) and at the Rs sites of the orthophenylenediamine 
(B, pg 23). Standard deprotection methodology such as ester 
hydrolysis may be used to unmask the free hydroxyl sub 
stituents. These derivatives exhibit significant solubility in 
aqueous media, up to 1 mM or better, yet they retain affinity 
for lipid rich regions which allows them to be useful in a 
biological environment. 
The photophysical properties of the tripyrroledimethine 
derived "expanded porphyrins' are reported; these com 
pounds show strong low energy optical absorptions in the 
690-880 nm spectral range as well as a high triplet quantum 
yield, and act as efficient photosensitizers for the production 
of singlet oxygen, for example, in methanol solution. 
Results indicate that these expanded porphyrin-like mac 
rocycles are efficient photosensitizers for the destruction of 
free HIV-1 and for the treatment of atheroma, benign and 
malignant tumors in vivo and infected mononuclear cells in 
blood. Altering the polarity and electrical charges of side 
groups of these macrocycles will alter markedly the degree, 
rate, and site(s) of binding to free enveloped viruses such as 
HIV-1 and to virally-infected peripheral mononuclear cells, 
thus modulating photosensitizer take-up and photosensitiza 
tion of leukemia or lymphoma cells contaminating bone 
marrow. The use of La(III), Lu(III) or In(III) rather than 
CdCII) for the production of singlet oxygen will reduce the 
toxicity of these compounds in any biomedical usage. A 
powerful technique is the use of these hydroxy-substituted 











photodynamic tumor therapy in the treatment of atheroma, 
and benign and malignant tumors. 
EXAMPLE 1 
Synthesis of Compounds 1-1 
This example describes the synthesis of compounds 
depicted in FIGS. 1A, 1B, 2A and 2B; the nonaromatic 
methylene-bridged macrocycle 1A, the expanded porphyrin 
named "texaphyrin' 1 and the nitrate salt of the cadmium 
(II) complex 1. 
All solvents and reagents were of reagent grade quality, 
purchased commercially, and used without further purifica 
tion. Sigma lipophilic Sephadex (LH-20-100) and Merck 
type 60 (230–400 mesh) silica gel were used for column 
chromatography. Melting points were recorded on a Mel 
temp Laboratory Devices capillary apparatus and are uncor 
rected. 
2.5-Bis(5-(benzylorycarbonyl)-3-ethyl- 4-methylpyrrol 
2-yl)methyl)-3,4-diethylpyrrole (2, FIG. 2A). 3,4-Dieth 
ylpyrrole (2A, FIG. 2A)' (0.6 g., 4.9 mmol), benzyl 5-(ac 
etoxymethyl)-3-methyl-4-ethyl-pyrrole-2-carboxylate (2, 
FIG. 2A)' (2.5 g, 7.9 mmol), and p-toluenesulfonic acid 
(0.15 g) were dissolved in 60 mL of absolute ethanol and 
heated at 60° C. for 8 h under nitrogen. The resulting 
suspension was reduced in volume to 30 mL and placed in 
the freezer for several hours. The product was then collected 
by filtration, washed with a small amount of cold ethanol, 
and recrystallized from dichloromethane-ethanol to afford a 
white powder (2.07 g. 82%); mp 211 C. NMR spectra and 
high resolution mass spectral data were obtained as 
described and are reported . 
2,5-Bis(3-ethyl-5-formyl-4-methylpyrrol-2-yl)methyl 
3,4-diethylpyrrole (2, FIG. 2A and 2B). The above diester 
(2) (4.5g, 7.1 mmol) was dissolved in 500 mL of dry THF 
containing 1 drop of triethylamine and hydrogenated over 
5% palladium-charcoal (250mg) at 1 atm H. pressure until 
the reaction was deemed complete by TLC. The catalyst was 
separated and the solution was taken to dryness on the rotary 
evaporator. Recrystallization from dichloromethane-hexane 
yielded 2 (3.2 g, quantitative) as a white powder which 
quickly develops a red hue upon standing in air: mp 
111-115° C. dec. The above diacid (3 g. 6.6 mmol) was 
dissolved in 5 mL of freshly distilled trifuoroacetic acid and 
heated at reflux for 5 min under nitrogen and allowed to cool 
to room temperature over the course of 10 min. The above 
heating and cooling sequence was repeated once more and 
the resulting dark oil was then cooled in an ice-salt bath. 
Freshly distilled triethylorthoformate (5 mL) was then added 
dropwise with efficient stirring. After 10 min the solution 
was poured into 300 mL of ice water and let stand 30 min. 
The dark red precipitate was collected by filtration and 
washed well with water. Ethanol (ca. 50 mL) was then used 
to wash the precipitate from the filter funnel into 350 mL of 
10% aqueous ammonia. The resulting yellow suspension 
was stirred well for an hour and then extracted with dichlo 
romethane (5x150 mL). The dichloromethane extracts were 
washed with water, dried over MgSO4, and evaporated to 
65 
dryness on the rotary evaporator to give 2 as an off-white 
mass. Two recrystallizations from chloroform-ethanol gave 
crystalline product (1.91 g, 68%) with mp 202-203° C. 
NMR spectra and high resolution mass spectra data were 
obtained as described and are reported '. 
45.9,24-Tetraethyl-10,23-dimethyl-13,20,25,26,27-pen 
taazapentacyclo[20.2.1.1.1.0']heptacosa- 3,5,8,10, 
12,14-(19), 15, 17,20,22,24-undecaene (1a). A. Acid-Cataly 
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sed Procedure. The diformyltripyrrane (2, FIGS. 2A and 
2B) (105 mg, 0.25 mmol) and o-phenylenediamine (27 mg., 
0.25 mmol) were dissolved, with heating, in a degassed 
mixture of 300 mL of dry benzene and 50 mL of absolute 
methanol. Concentrated HCl (0.05 mL) was then added and 
the resulting gold solution heated at reflux for 24 h under 
nitrogen. After cooling, solid KCO (20 mg) was added and 
the solution filtered through MgSO4. The solvent was then 
removed on the rotary evaporator and the resulting product 
dissolved in 50 mL of CH2Cl and refiltered (to remove 
unreacted 2). Heptane (100 mL) was added to the filtrate 
and the volume reduced to 50 mL on the rotary evaporator 
whereupon the flask was capped and placed in the freezer 
overnight. The resulting white powder was then collected by 
filtration, washed with hexane, and dried in vacuo to yield la 
(55 mg, 44%); mp 1889-190° C. 
Metal Template Procedure. The diformyltripyrrane 2 and 
o-phenylenediamine reactants were condensed together on a 
0.25-mmol scale exactly as described above except that 1.0 
equiv of either Pb(SCN) (80 mg) or UOC (85 mg) was 
added to the boiling solution at the outset of the reaction. 
Following workup as outlined above, 68 mg (69%) and 60 
mg (61%) of 1 were obtained respectively for the Pb'- and 
UO,” -catalyzed reactions. The products produced in this 
manner proved identical with that prepared by procedure A. 
NMR spectra and high resolution mass spectra data were 
obtained as described and are reported'. 
45.9,24-Tetraethyl-10,23-dimethyl-13,20,25,26,27-pen 
taazapentacyclo (20.2.1.1.1'.0''' heptacosa-1,3,5,7, 
9,11(27), 12, 14,16,18,20,22(25),23-tridocaene, free-base 
"texaphyrin” 1. Macrocycle 1 (50 mg, 0.1 mmol) was 
stirred in methanol/chloroform (150 ml, v/v/2/1) in the presence of N,N,N',N'-tetramethyl-1,8-diaminonaphthalene 
("proton sponge') for one day at room temperature. The 
reaction mixture was then poured into ice water. The organic 
layer was separated and washed with aqueous ammonium 
chloride solution and then brine (a saturated solution of 
sodium chloride in water). Following concentration on a 
rotary evaporator, the crude material was purified by chro 
matography on SEPHADEX using first pure chloroform and 
then chloroform/methanol (v/v/10/1) as eluents. After sev 
eral faster red bands were discarded, a dark green band was 
collected, concentrated in vacuo, and recrystallized from 
chloroform/n-hexane. to give the sp’ form of the ligand as 
a dark green powder in yields ranging from 3-12% with the 
better yields only being obtained on rare occasions. Spectral 
data are reported in the parent patent application Ser. No. 
07/771,393. 
The preparation of complex 1.NO was as follows: the 
reduced sp form of the macrocyclic compound (1A) (40 mg, 
0.08 mmol) was stirred with cadmium nitrate tetrahydrate 
(31 mg, 0.1 mmol) in chloroform/methanol (150 ml, v/v/=%) 
for 1 day. The dark green reaction mixture was then con 
centrated and purified by chromatography on silica gel as 
described above. The resulting crude material was then 
recrystallized from chloroform/n-hexane to give analytically 
pure 1.NO in 27% yield. Under the reaction conditions 
both ligand oxidation and metal complexation take place 
spontaneously. Spectral data are reported in the parent patent 
application Ser. No. 07/771,393. 
The structure of compound I suggests that it can be 
formulated as either an 187t-electron benzannelated 18 
annulene or as an overall 22 at-electron system; in either case 
an aromatic structure is defined. The proton NMR spectrum 
of complex 1.N.O.(HNO) (see FIG.3A) is consistent with 
the proposed aromaticity. For the most part, complex 












lar to those observed for compound 1. As would be 
expected in the presence of a strong diamagnetic ring 
current, however, the alkyl, imine, and aromatic peaks are all 
shifted to lower field. Furthermore, the bridging methylene 
signals of compound 1A (at 84.0)' are replaced by a sharp 
singlet, at ca. 9.2 ppm, ascribable to the bridging methine 
protons. The chemical shift of this "meso signal is similar 
to that observed for Cd(OEP)'' (8-10.0), an appropriate 
187t-electron aromatic reference system, and is also similar 
to that observed for the free-base form of decamethylsap 
phyrin (8 - 11.7), a 22 at-electron pyrrole-containing 
macrocycle. 
The optical spectrum of complex 1.NO (FIG. 4A) bears 
some resemblance to those of other aromatic pyrrole-con 
taining macrocycles''' and provides further support for 
the proposed aromatic structure. The dominant transition is 
a Soret-like band at 424 nm (e=72,700), which is consider 
ably less intense than that seen for Cd(OEP)(pyr)' . 
=421 nm, e= 288,000. This peak is flanked by exception 
ally strong N- and Q-like bands at higher and lower energies. 
As would be expected for a larger TC system, both the lowest 
energy Q-like absorption (=767.5 nm, e=41,200) and 
emission (A=792 nm)) bands of complex 1.NO are 
substantially red-shifted (by ca. 200 nm) as compared to 
those of typical cadmium porphyrins.'' 
The molecular structure of the bis-pyridine adduct, deter 
mined by X-ray diffraction analysis confirms the aromatic 
nature of the ligand.' The central five nitrogen donor atoms 
of the complex are essentially coplanar and define a near 
circular cavity with a center-to-nitrogen radius of ca. 2.39 A 
which is roughly 20% larger than that found in metallopor 
phyrins.' The cd atom lies in the plane of the central Ns 
binding core. The structure of the "expanded porphyrin' 
thus differs dramatically from that of CdTPP’ or CdTPP 
(dioxane)” in which the cadmium atom lies out of the 
porphyrin N, donor plane (by 0.58 and 0.32 A respectively). 
Moreover, in contrast to cadmium porphyrins, for which a 
five-coordinate square-pyramidal geometry is preferred and 
to which only a single pyridine molecule will bind,” in the 
bis-pyridine adduct, the cadmium atom is seven-coordinate, 
being complexed by two apical pyridine ligands. The con 
figuration about the Cd atomis thus pentagonal bipyramidal; 
a rare but not unknown geometry for cadmium(II) com plexes.’ 
Under neutral conditions complex 1 appears to be more 
stable than cadmium porphyrins: Whereas treatment of 
CdTPP or CdTPP(pyr) with aqueous NaS leads to cation 
loss and precipitation of CdS, in the case of complex 1 no 
demetallation takes place. (Exposure to aqueous acid, how 
ever, leads to hydrolysis of the macrocycle.) Indeed, it has 
not been possible to prepare the free-base ligand 1 by 
demetallation. The tripyrroledimethine-derived free-base 
ligand 1 was synthesized directly from 1A by stirring in 
air-saturated chloroform-methanol containing N,N,N',N'- 
tetramethyl-1,8-diaminonaphthalene.' Although the yield 
is low (s12%),' once formed, compound 1 appears to be 
quite stable: It undergoes decomposition far more slowly 
than compound 1." Presumably, this is a reflection of the 
aromatic stabilization present in compound 1. A further 
indication of the aromatic nature of the free-base "expanded 
porphyrin" 1 is the observation of an internal pyrrole NH 
signal at 8= 0.90, which is shifted uDfield by over 10 ppm 
as compared to the pyrrolic protons present in the reduced 
macrocycle 1.' This shift parallels that seen when the 
sp-linked macrocycle, octaethylporphyrinogen (6(NH)= 
6.9),' is oxidized to the corresponding porphyrin, HOEP 
(6 (NH)= -3.74).' This suggests that the diamagnetic ring 
5,569,759 
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current present in compound 1 is similar in strength to that 
of the porphyrins. 
EXAMPLE 2 
Synthesis of compounds 5A-5. 
The presence in texaphyrin of a near circular pentadentate 
binding core which is roughly 20% larger than that of the 
porphyrins,' coupled with the realization that almost iden 
tical ionic radii pertain for hexacoordinate Cd' (r=0.92 A) 
and Gd" (r=0.94 A), prompted exploration of the general 
lanthanide binding properties of this new monoanionic por 
phyrin-like ligand. The synthesis and characterization of a 
water-stable gadolinium(III) complex (5) derived formally 
from a 16,17-dimethyl substituted analogue (5) of the 
original "expanded porphyrin” system is described in this 
example. 
All solvents and reagents were of reagent grade quality, 
purchased commercially, and used without further purifica 
tion. Sigma lipophilic SEPHADEX (LH-20-100) and Merck 
type 60 (230-400 mesh) silica gel were used for column 
chromatography. 
Compound 5 is the metal adduct of ligand 5A which was 
obtained in ca. 90% yield by condensing 1,2-diamino-4,5- 
dimethylbenzene with 2,5-Bis-(3-ethyl-5-formyl-4-meth 
ylpyrrol-2-ylmethyl)-3,4-diethylpyrrole under acid cata 
lyzed conditions identical to those used to prepare 1.' The 
sp form of ligand 5 (42 mg, 0.08 mmol) was stirred with 
gadolinium acetate tetrahydrate (122 mg, 0.3 mmol) and 
Proton SpongeTM, N, N, N, N'-tetramethyl-1,8-diaminon 






(150 ml, viv /2) for one day at room temperature. The dark 
green reaction mixture was concentrated under reduced 
pressure and chromatographed through silica gel (25 cm.X 
1.5 cm.) which was pretreated with chloroform/triethy 
lamine (50 ml, w/v 25/1). Chloroform/triethylamine (25/1) 
and chloroform/methanol/triethylamine 25/2.5/1 v/v) was 
used as eluents. A dark redband was first collected followed 
by two green bands. The last green band, which showed a 
clear aromatic pattern by UV/VIS, was concentrated and 
recrystallized from chloroform/n-hexane to give 14 mg 
(22%) of the Gd complex 5. 
Treatment of compound 5 with Gd(OAc), Eu(OAc), 
and Sm(OAc) under reaction and work-up conditions simi 
lar to those used to obtain 1, then gave the cationic 
complexes 5, 5, and 5, as their dihydroxide adducts, in 
22%, 33%, and 37% yields respectively. As judged by the IR 
and microanalytical data, under the reaction and work up 
conditions, hydroxide anions serve to displace the acetate 
ligands presumably present following the initial metal inser 
tion procedure. 
The new lanthanide complexes reported here are unique 
in several ways. For instance, as judged by fast atom 
bombardment mass spectrometric (FABMS) analysis, com 
plexes 1-5 are mononuclear 1:1 species, a conclusion that 
is further supported, by both high resolution FAB MS 
accurate molecular weight determinations and combustion 
analysis. In other words, we have found no evidence of 1:2 
metal to ligand "sandwich' systems, or higher order com 
binations as are often found in the case of the better studied 
lanthanide porphyrins.' 
The electronic spectra represents a second remarkable 
feature of these new materials. The lanthanide complexes 
isolated to date display a dominant Soret-like transition in 
the 435-455 nm region which is considerably less intense 









and show a prominent low energy Q-type band in the 
760-800 nm region. This latter feature is diagnostic of this 
class of 22 at-electron “expanded porphyrins' and is both 
considerably more intense and substantially red-shifted (by 
ca. 200 nm) as compared to the corresponding transitions in 
suitable reference lanthanide porphyrins (e.g., (GdCTPPS) 
", =575 nm). 
Within the context of these general observations, it is 
interesting to note that complexes derived from the some 
what more electron rich ligand 5 all display Q-type bands 
that are blue shifted by ca. 5-15 nm as compared to those 
obtained from the original texaphyrin 1 
A third notable property of complexes 5-5 is their high 
solubility in both chloroform and methanol. The fact that 
these three complexes are also moderately soluble (to 
roughly 103M concentrations) in 1:1 (v.v.) methanol/water 
mixtures was of particular interest. For instance, a 3.5x105 
M solution of the gadolinium complex 5 in 1:1 (v.V.) 
methanol/water at ambient temperature shows less than 10% 
bleaching of the Soret and Q-type bands when monitored 
spectroscopically over the course of 2 weeks. This suggests 
that the half-life for decomplexation and/or decomposition 
of this complex is 2100 days under these conditions. Under 
the conditions of the experiment described above, no detect 
able shifts in the position of the Q-type band are observed 
yet the Q-type transition of the free-base 5 falls ca. 20 mm 
to the blue of that of 5. Thus, shifts in this direction would 
be expected if simple demetalation were the dominant 
pathway leading to the small quantity of observed spectral 
bleaching. 
The strong hydrolyric stability of complexes 5-5 is in 
marked contrast to that observed for simple, water soluble 
gadolinium porphyrins, such as GdCTPPS", which 
undergo water-induced demetalation in the course of several 
days when exposed to an aqueous environment." It thus 
appears likely that gadolinium(III) complexes derived from 
the new texaphyrin ligand 5, or its analogues, should 
provide the basis for developing new paramagnetic contrast 
reagents for use in MRI applications. In addition, the ease of 
preparation and stable mononuclear nature of complexes 
5-5 suggests that such expanded porphyrin ligands might 
provide the basis for extending further the relatively under 
developed coordination chemistry of the lanthanides. 
EXAMPLE 3 
Synthesis of texaphyrin derivative B2. 
Nomenclature. The trivial abbreviations assigned to the 
hydroxylated derivatives of texaphyrin (TXP) in this and 
following examples refer to the number of hydroxyl groups 
attached to the benzene ring portion (B) and the tripyrrole 
(T) portion of the molecule. 
General Information. H and 'C NMR spectra were 
obtained on a General Electric QE-300 (300 MHz.) spec 
trometer. Electronic spectra were recorded on a Beckman 
DU-7 spectrophotometer in CHCI Infrared spectra were 
recorded, as KBr pellets, from 4000 to 600 cm on a 
Nicolet 510P FTIR spectrophotometer. Chemical ionization 
mass spectrometric analyses (CIMS) were made using a 
Finnigan MAT4023. Low resolution and high resolution fast 
atom bombardment mass spectrometry (FAB MS) were 
performed with a Finnigan-MATTSQ-70 and VGZAB-2E 
instruments, respectively. A nitrobenzyl alcohol (NBA) 
matrix was utilized with CHCl as the co-solvent. Elemental 
analyses were performed by Atlantic Microlab, Inc. Melting 




Materials. All solvents and reagents were of reagent grade 
quality, purchased commercially, and used as received. 
Merck Type 60 (230–400 mesh) silica gel was used for 
column chromatography. Thin-layer chromatography was 
performed on commercially prepared Whatman type silica 
gel 60A plates. 
1,2-bis(2-carboxy)ethoxy)-4,5-dinitrobenzene. 6, FIG. 
6. To a well stirred solution of o-bis((3-hydroxypropyl)oxy 
)benzene' (5.0g, 22 mmol) in 30 mL glacial acetic acid 
cooled to 15° C., 20 mL of concentrated nitric acid (70%) 
was added dropwise over a period of 15 minutes. The 
temperature was held below 40° C. by cooling and proper 
regulation of the rate of acid addition. After the addition, the 
yellow solution was stirred at room temperature for 15 
minutes. Here, the solution was cooled again to 15° C. and 
50 mL of fuming nitric acid (90%) was added dropwise over 
a period of 30 minutes. The orange solution was brought to 
room temperature and stirred for approximately 48 hours. 
After 48 hours, the reaction solution was checked by TLC, 
which displayed only one low R spot, the diacid. Therefore, 
the orange solution was poured onto 600 mL. of ice in a 1 
liter beaker. The precipitated dinitro product was filtered, 
washed with water (1000 mL) until free from acid and dried 
in vacuo for 24 hours. The crude product was recrystallized 
from acetone/n-hexanes to yield the diacid as fluffy yellow 
needles (4.20 grams, 55.2%). For the diacid: "H NT(R 
(d-acetone) 8: 2.87 (t, 4H, OCH2CHCO2H), 4.49 (t, 4H, 
OCHCHCOH), 7.71 (s, 2 H, Ar-H), 9-10 (brs, 2 H, 
COH). 'C NMR (d-acetone) 8: 33.76, 66.57, 109.85, 
137.14, 152.06, 171.51. EI MS, m/z (rel. intensity: 346 
(100)) 
1,2-bis((3-hydroxypropyl)oxy)-4,5-dinitrobensene. 6, 
FIG. 6. In a dry 500 mL round bottom flask, equipped with 
a 125 mL pressure equalized dropping funnel, 1,2-bis(( 
2-carboxy)ethoxy)-4,5-dinitrobenzene (5.0 g, 14.5 mmol) 
was dissolved in 50 mL dry THF (distilled over ketyl) and 
stirred at 10-10°C. under nitrogen. To the resulting clear 
solution, 120 mL of BH THF (1M) was added dropwise 
over a period of 30 minutes. After the borane addition, the 
reaction mixture was stirred an additional 5 minutes at 10 
C. and then it was brought up to room temperature. The 
formation of the diol product was followed by TLC and the 
reaction was deemed complete after approximately 2 hours. 
The borane solution was quenched by careful addition of 65 
mL of absolute methanol (Careful: frothing occurs!). After 
stirring the yellow solution for 30 minutes, it was concen 
trated to a bright yellow solid on a rotary evaporator. The 
crude solid was dissolved in 200 mL ethyl acetate and 
washed with 4M sodium acetate (2x100 mL), water (2x100 
mL) and then brine (50 mL). The organic layer was dried 
over MgSO and concentrated to dryness on a rotary evapo 
rator. The crude product was recrystallized from acetone/n- 
hexanes to afford 4.12 grams (90%) of orange needles. For 
the diol: mp 129°-130° C.; H NMR (CDCl) 5: 2.10 (p, 4 
H, OCHCHCHOH), 3.81 (t, 4 H, OCHCHCH-OH), 
4.28 (t, 4H, OCHCHCH-OH), 741 (s, 2 H, Ar-H). 'C 
NMR (d-acetone) 8:32.52, 58.50, 67.81, 107.88, 137.03, 
152.47. EIMS, m/z (rel. intensity): 316 (100); HRMS (M'.) 
316.0914 (calcd. for C2HNO:316.0907). 
1,2-Diamino-4,5-bis(3'-hydroxypropyl)oxybensene, 6, 
FIG. 6. The diamine was obtained by reduction of the 
corresponding 1,2-bis((3-hydroxypropyl)oxy)-4,5-dini 
trobenzene (3.0 g, 9.6 mmol) with hydrazine hydrate (4.7 
mL, 96.2 mmol) and 10% palladium on carbon (200mg) in 
120 mL refluxing absolute ethanol. The resulting brown 
suspension bubbled for approximately 15-20 minutes and 












was deemed complete as judged by TLC (alow Rspot). The 
reaction solution was hot filtered through celite into a dry 
flask, covered with aluminum foil, and then concentrated to 
a gray solid. The diamine was recrystallized from hot 
acetone/n-hexanes to yield 2.20 grams (91%) of an off-white 
fine powder. For the diamine: mp 115°-117 C.; H NMR 
(d-DMSO) 8: 1.76 (p, 4 H, OCHCHCH-OH), 3.53 (q, 4 
H, OCHCHCH-OH), 3.82 (t, 4 H, OCHCHCH-OH), 
4.06 (s, 4H, NH),444 (t, 2 H, OH), 6.25 (s, 2 H, ArH). 'C 
NMR (d-DMSO) 8:42.68, 67.84, 77.08, 114.95, 139.01, 
150.63. EIMS, m/z (rel. intensity): 256 (100); HRMS (M'.) 
256.1420 (calcd for C2HNO: 256.1423). 
4.5,9.24 -Tetraethyl-16,17-bis((3-hydrorypropyl)oxy)- 
1 9,23-dimethyl 13,20,25,26,27-pentaazapentacyclo 
20.2.1.13.6.18.11.04.19 -heptacosa-3,5,8,10,12,14(19), 
15, 17,2022,24-undecaene. sp. B2 TXP, 6, FIG. 6. This 
macrocycle was prepared in >90% yield from 1,2-diamino 
4,5-bis((3-hydroxypropyl)oxy)benzene and 2,5-bis((3- 
ethyl-5-formyl-4-methylpyrrol-2-yl)methyl)- 3,4-diethyl 
pyrrole by using the acid-catalyzed procedure reported ear 
lier for the preparation of the reduced sp texaphyrin, see 
Example 1. For B2 sp texaphyrin: mp 190° C. dec; "H 
NMR (CDC) 8: 1.05 (t, 6 H, CHCH.), 1.12 (t, 6 H, 
CHCH), 2.00 (t, 4 H, OCHCHCHOH), 2.28 (s, 6 H, 
pyrr-CH), 2.35 (q, 4 H, CHCH), 2.48 (q, 4H CHCH), 
3.00-3.50 (bs, 2 H, OH), 3.78 (t, 4H, OCHCHCH-OH), 
3.93 (s, 4 H, (pyrr)-CH2), 4.19 (s, 4 H, 
OCHCHCH-OH), 7.16 (s, 2 H, ArH), 8.34 (s, 2 H, CHN), 
11.16 (s, 1 H, NH), 12.04 (s, 2 H, NH); C NMR (CDC1) 
8: 9.65, 15.45, 16.61, 17.23, 17.60, 22.18, 31.71, 60.75, 
68.58, 100.86, 120.23, 120.37, 124.97, 125.06, 130.05, 
133.86, 140.16, 140.86, 147.62; UV/vis 369 nm, CI 
MS (M) 642; CI HRMS (M) 642.4039 (calcd for 
CHNO: 642.4019). 




27),12,14(19), 15,1720,22(25).23-tridecaene LuB2Txp' 
6, FIG. 6. A mixture of the reduced texaphyrin ligand, 
4,5,9,24-tetraethyl- 16,17-bis((3-hydroxypropyl)oxy)-10, 
23-dimethyl- 13,20,25,26,27-pentaazapentacyclo[20.2.1. 13, 
6.1.0'']heptacosa 3,5,8,10,12,14(19), 15, 17,2022,24 
undecaene (100 mg., 0.16 mmol), lutetium (III) nitrate 
hydrate (177 mg, 0.47 mmol) and triethylamine (10 drops) 
were combined in 150 mL of refluxing methanol for 12-24 
hours. The dark green reaction mixture was concentrated on 
a rotary evaporator to dryness and dried in vacuo for 24 
hours. The crude complex was dissolved in a 100 mL 1:1. 
(v/v) mixture of chloroform and methanol, filtered through 
celite and concentrated to 20 mL. A small amount of silica 
gel (approx. 3 grams) was added to the flask and then the 
dark green solution was carefully concentrated to dryness on 
a rotary evaporator. The silica was dried for 2 hours in 
vacuo, then it was loaded on a chloroform packed silica 
column and the complex was purified by first using neat 
chloroform and then increasing concentrations of methanol 
in chloroform (0%-20%) as eluents. The dark green band 
collected from the column was concentrated to dryness on a 
rotary evaporator and recrystallized from chloroform/metha 
nol/diethyl ether to yield 50 mg (ca. 35%) of the lutetium 
(III) B2 texaphyrin. For the Lu (III) complex: 'H NMR 
(CDC1/CDOH)6: 1.82-191 (m, 12 H, CHCH), 2.39 (m, 
4 H, OCHCHCH-OH), 3.32 (m, 4H, OCHCHCH-OH), 
3.39 (s, 6 H, pyrr-CH), 3.92-4.04 (m, 12 H, 
OCHCHCH-OH and CHCH), 9.52 (s, 2 H, CH=C), 
10.24 (s, 2 H, ArH), 12.23 (s, 2 H, CH=N); UV/vis: 
420.0, 477.5, 730.0; FAB MS M 811. 
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Otherlanthanide and rare earth-like metal complexes may 
be synthesized including the Gd", Lu", La", In", and 
Dy" complexes. 
EXAMPLE 4 
Synthesis of B2T2. TXP, see FIGS. 7A and 7B. 
2,5-Bis(5-bensyloxycarbonyl-4-methyl- 3-methoxycar 
bonylethylpyrrol-2-yl)methyl-3,4-diethylpyrrole. 7, FIG. 
7A. In a 500 mL round bottom flask was placed 250 mL of 
ethanol from an unopened bottle and this was then purged 
with dry nitrogen for ten minutes. 3,4-Diethylpyrrole 7 
(1.29 g, 0.01 mol) and 2-acetoxymethyl- 5-benzyloxycar 
bonyl-4-methyl-3-methoxycarbonylethylpyrrole 7A (7.83 g, 
0.02 mol) were added and the mixture heated until all of the 
pyrroles dissolved. p-Toluenesulfonic acid (65 mg) was 
added and the reaction temperature maintained at 60°C. The 
reaction slowly changed color from a clear yellow to a dark 
red with the product precipitating out of the solution as the 
reaction progressed. After ten hours the reaction was cooled 
to room temperature, the volume reduced to one half on a 
rotary evaporator, and then placed in the freezer for several 
hours. The product was collected by filtration, washed with 
a small amount of cold ethanol to afford 4.61 g of an off 
white fine powder (61%); H NMR (CDC), 250 MHz): 8 
1.14 (6 H, t, CHCH.), 2.23 (6 H, s, pyrrole-CH), 2.31 (4 
H, t, CHCHCOCH), 2.50 (4H, q, CHCH), 2.64 (4 H, 
t, CHCHCOCH), 3.60 (10 H, brs, CHCO-and (pyr 
role)-CH2), 4.44 (4 H, brs, CHCH), 6.99–7.02 (4 H, 
m, aromatic), 7.22-7.26 (6 H, m, aromatic), 8.72 (1 H, s, 
NH), 10.88 (2 H, brs, NH); C NMR (CDC, 250 MHz): 
8 1097, 16.78, 17.71, 19.40, 22.07, 35.09, 51.46, 65.32, 
117.37, 119.34, 122.14, 126.58, 126.79, 127.36,128.19, 
133.55, 136,62, 162.35, 173.49; CIMS (M+H) 750; HRMS 
749.3676 (calc. for CHNOs: 749.3676). 
2,5-Bis(5-benzyloxycarbonyl-3-hydroxypropyl-4-meth 
ylpyrrol-2-yl)methyl-3,4-diethylpyrrole. 7, FIG. 7A. 2,5- 
Bis(5-benzyloxycarbonyl-4-methyl-3-methoxycarbonyl 
ethylpyrrol- 2-yl)methyl-3,4-diethylpyrrole 7 (5.00 g, 
0.007 mol) was placed in a three necked 100 mL round 
bottom flask and vacuum dried for at least 30 minutes. The 
flask was equipped with a thermometer, an addition funnel, 
a nitrogen inlet tube, and a magnetic stir bar. After the 
tripyrrane was partially.dissolved into 10 mL of dry THF, 29 
mL of borane (1MBH in THF) was added dropwise with 
stirring. The reaction became mildly exothermic and was 
cooled with a cool water bath. The tripyrrane slowly dis 
solved to form a homogeneous orange solution which turned 
to a bright fluorescent orange color as the reaction went to 
completion. After stirring the reaction for one hour at room 
temperature, the reaction was quenched by adding methanol 
dropwise until the vigorous effervescence ceased. The sol 
vents were removed under reduced pressure and the result 
ing white solid redissolved into CH. The tripyrrane was 
washed three times with 0.5M HCl (200 mL total), dried 
over anhydrous KCO, filtered, and the CHCl, removed 
under reduced pressure until crystals of the tripyrrane just 
started to form. Hexanes (50 mL) was added and the 
tripyrrane allowed to crystallize in the freezer for several 
hours. The product was filtered and again recrystallized from 
CHCl/ethanol. The product was collected by filtration and 
vacuum dried to yield 3.69 g of an orangish white solid 
(76%); mp 1729-173° C.; H NMR (CDC1, 300 MHz): 8 
1.11 (6H, t, CHCH), 1.57 (4H, p, CHCHCH-OH), 2.23 
(6 H, s, pyrrole-CH), 2.39–2.49 (8 H, m, CHCH and 
CHCHCH-OH), 3.50 (4H, t, CHCHCH-OH), 3.66(4H, 













(4H, m, aromatic), 7.25-7.30 (6H, m, aromatic), 8.64 (1 H, 
s, NH),992 (2 H, s, NH); C NMR (CDCl300 MHZ): 8 
10.97, 16.72, 17.68, 20.00, 22.38, 33.22, 62.01, 65.4.3, 
117.20, 119.75, 120.72, 122.24, 127.23, 127.62, 128.30, 
132.95, 136.60, 162.13; FAB MS (M) 693. 
2,5-Bis(3-acetoxypropyl-5-bensyloxycarbonyl- 4-meth 
ylpyrrol-2-yl)methyl)-3,4-diethylpyrrole. 7, FIG. 7A. 2,5- 
Bis(5-benzyloxycarbonyl- 3-hydroxypropyl-4-methylpyr 
rol-2-yl)methyl-3,4-diethylpyrrole 7 (36.4g, 0.05 mol) 
was placed in a 1 L three necked round bottom flask and 
dried under vacuum for at least 30 minutes. The flask was 
equipped with a dropping funnel, a thermometer, a nitrogen 
inlet tube, and a magnetic stir bar. CH2Cl2 (600 mL dried 
over Cah) was added to the tripyrrane and stirred under 
nitrogen to form an orange suspension. Pyridine (10.5 mL) 
was added directly to the flask followed by acetyl chloride 
(9.5 mL) in 50 mL of dry CHCl which was added dropwise 
from the addition funnel at such a rate that the temperature 
of the reaction didn't exceed 25 C. An ice/water bath was 
used to cool the reaction. The tripyrrane slowly dissolved as 
the acetyl chloride was added to form a dark red homoge 
neous solution. The reaction was stirred at room temperature 
for approx. 3 hours then quenched with sat. aq. NaHCO. 
The organic layer was separated, washed three times with 
0.5M HCl, then once with sat. NaHCO. The organic layer 
was separated, dried over MgSO, filtered, then reduced to 
dryness on the rotary evaporator. The orange solid was dried 
in vacuo for several hours then redissolved into CH2Cl and 
crystallized using hexanes. 36.8 g of an orange colored 
product was obtained (89%). A purer product can be 
obtained by recrystallization from CHCl/ethanol. For 
tripyrrane 7: mp 127°–129° C.; H NMR (CDC1, 300 
MHz): 8 1.14 (6 H, t, CHCH), 1.67 (4 H, p, 
CHCHCHOAc), 2.04 (6 H, s, CHCOCH), 2.22 (6 H, 
s, pyrrole-CH), 2.37 (4H, t, CHCHCHOAc), 2.48 (4H, 
q, CHCH), 3.57 (4 H, s, (pyrrole)-CH2), 3.98 (4H, t, 
CHCHCHOAc), 4.45 (4H, s, CH-CH2), 7.01-7.03 (4 
H, m, aromatic), 7.23-7.29 (6 H, m, aromatic), 8.69 (2 H, s, 
NH), 10.95 (1 H, s, NH); C NMR (CDC1, 300 MHz): 8 
11.06, 16.89, 17.74, 20.19, 20.93, 21.98, 29.70, 63.83, 
65.31, 117.38, 118.81, 119.89, 122.24, 126.42, 126.68, 
127.24, 128.11, 133.53, 136.73, 162.62, 171.12; CI MS 
(M) 777; HRMS (M+H), 778.4060 (calc. for 
CHNO3, 778.4067). 
2.5-Bis(3-acetoxypropyl-5-carboxyl-4-methylpyrrol-2- 
yl) methyl-3,4-diethylpyrrole. 7, FIG. 7A 2.5-Bis(3-ac 
etoxypropyl-5-benzyloxycarbonyl-4-methylpyrrol-2-yl)m- 
ethyl-3,4-diethylpyrrole 7 (15.0g, 0.02 mol) was placed in 
a 500 mL side arm round bottom flask and dried under 
vacuum for at least 30 minutes. After dissolving the tripyr 
rane into 400 mL of dry THF, 10% Pd on carbon (0.75 g) and 
two drops of triethylamine were added and the mixture 
stirred at room temperature under one atm. of H2. After 15 
hrs. celite was added to the mixture and the catalyst was 
filtered off. The light orange solution was reduced to one half 
volume under reduce pressure, then 100 mL of heptane was 
added and the solution further reduced in volume until 
crystals of the tripyrrane diacid just started to appear. The 
tripyrrane was allowed to crystallize in the freezer for 
several hours and then filtered to yield a white color solid 
which developed a reddish hue on standing in air. 10.94 
grams of product was obtained (96%): mp 146-148 dec; H 
NMR (CDC1,300 MHz): 81.09 (6H, t, CHCH), 1.76 (4 
H, p, CHCHCHOAc), 2.03 (6 H, s, CH-CO), 2.23 (6H, 
s, pyrrole-CH), 2.42 (4 H, q, CHCH), 2.49 (4 H, t, 
CHCHCHOAc), 3.77 (4 H, s, (pyrrole)-CH), 4.01 (4 
H, t, CHCHCHOAc), 8.23 (1 H, s, NH), 9.29 (2 H, s, 




methyl-3,4-diethylpyrrole. 7, FIG. 7A and 7B. 2,5-Bis(3- 
acetoxypropyl-5-carboxyl-4-methylpyrrol- 2-yl)methyl)- 
3,4-diethylpyrrole 7 (5.80 g, 0.0097 mol) was placed in a 
250 mL round bottomed flask equipped with a nitrogen inlet 
and a magnetic stir bar. At room temperature under nitrogen 
trifluoroacetic acid (16 mL) was added to the tripyrrane 
dropwise via syringe. The tripyrrane dissolved with visible 
evolution of CO to form a dark orange solution. The 
reaction was stirred at room temperature for 10-15 minutes, 
then cooled to -20° C. using a dry ice/CCl bath. Freshly 
distilled triethylorthoformate (16 mL, dried over CaH) was 
added dropwise via syringe to produce a deep red solution 
which was stirred an additional ten minutes at -20°C. The 
cold bath was removed and 100 mL of water was added 
slowly to the solution. A precipitate formed during addition 
of the water and the resulting orange suspension was stirred 
at room temperature for 20–30 minutes. The product was 
collected by filtration, washed several times with water, and 
resuspended in 1:150% aqueous NH.OH/Ethanol (240 mL). 
The yellow/brown suspension was stirred for one hour at 
room temperature, filtered, washed several times with water 
and then washed with a small amount of cold ethanol. The 
tripyrrane was recrystallized from CH-Cl/ethanol to yield 
4.50 g of a reddish color solid (82%); mp 179°-181° C.; H 
NMR (CDC1,300 MHz): 81.11 (6H, t, CHCH.), 1.67 (4 
H, p, CHCHCHOAc), 2.05 (6 H, s, CHCO-), 2.19 (6 
H, s, pyrrole-CH), 2.42-249 (8 H, m, CHCH and 
CHCHCHOAc), 3.83 (4H, s, (pyrrole)-CH), 3.99 (4 
H, t, CHCHCHOAc), 9.07 (2 H, s, CHO), 9.42 (1 H, s, 
NH), 10.70 (2 H, s, NH); C NMR (CDC1,300 MHz): 8 
8.75, 16.55, 17.62, 1998, 20.85, 22.56, 29.04, 63.71, 
120.26, 121.41, 121.65, 128.02, 132.81, 138.52, 171.08, 
175.38: CIMS (M+1)"567; HRMS (M+H)566.3208 (calc 
for CHNO 566.3230). 
2.5-Bis(5-formyl-3-hydroxypropyl-4-methylpyrrol- 2-yl) 
methyl-3,4-diethylpyrrole. 7, FIG. 7B. 2,5-Bis(3-acetox 
ypropyl-5-formyl-4-methylpyrrol- 2-yl)methyl)-3,4-dieth 
ylpyrrole 7 (5.98 g, 0.011 mol) and LiOH (1.76 g, 0.042 
mol) were added to 400 mL of 95% methanol, which had 
been degassed with nitrogen prior to use, and the mixture 
heated to reflux under a nitrogen atmosphere. The reaction 
became homogeneous when heated. After heating for 1.25 
hours, the reaction was allowed to cool to room temperature. 
The product precipitated as a tan color solid as the reaction 
cooled. The volume of the reaction mixture was reduced to 
75 mL on a rotary evaporator and the resulting slurry placed 
in the freezer for several hours. The product was filtered and 
then purified by forming a slurry with 400 mL of methanol 
and 50 mL of water and heating close to boiling. The slurry 
was first cooled to room temperature, reduced to /2 volume 
under reduced pressure, and placed in the freezer for several 
hours. The product was collected by filtration and vacuum 
dried to yield 4.96 g of a tan powder (94%): 'H NMR 
(CDOD,300 MHz): 80.96 (6H, t, CH,CH), 1.49 (4H, p, 
CHCHCH-OH), 2.25 (6H, s, pyrrole-CH), 2.32-243 (8 
H, m, CHCH and CHCHCH-OH), 3.46 (4 H, t, 
CHCHCH-OH), 3.85 (4H, s, (pyrrole)-CH2)9.34 (2H, 














14(19), 15, 17,2022,24-undecaene. 7, FIG. 7B. 2,5-Bis(5- 
formyl-3-hydroxypropyl-4-methylpyrrol-2-yl)methyl)-3,4- 
diethylpyrrole 7 (1.00 g, 0.002 mol) and 1,2-diamino-4,5- 
bis( 3-hydroxypropyloxy)benzene 7 (0.52g, 0.002 mol) 
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were placed in a 2 L round bottom flask with 1000 mL of 
toluene and 200 mL of methanol. The solvents were purged 
with nitrogen prior to use. Concentrated HCl (0.5 mL) was 
added and the reaction heated to reflux under nitrogen. The 
reaction went from a clear suspension of starting materials 
to a dark red homogeneous solution as the reaction pro 
ceeded. After 10 hours the reaction was cooled to room 
temperature and the solvents removed under reduced pres 
sure until the product precipitated out of solution. The 
remainder of the solvent was decanted off and the macro 
cycle dried under vacuum. The dark red product was used 
without further purification (90-100%): mp 181° C.-dec; 
HNMR (CDOD,300 MHz): 81.11 (6H, t, CH,CH), 1.76 
(4 H, p, pyrrole-CH2CHCH-OH), 2.03 (4 H, p, 
OCHCHCH-OH), 2.36 (6 H, s, pyrrole-CH), 2.46 (4H, 
q, CHCH), 2.64 (4 H, t, pyrrole-CHCHCH-OH), 3.61 (4 
H, t, pyrrole-CHCHCH-OH), 3.77 (4 H, t, 
OCH2CHCH-OH), 4.10 (4 H, s, (pyrrole)-C), 4.22 (4 
H, t, OCHCHCHOH), 7.41 (2 H, s, aromatic), 8.30 (2 H, 
s, CHN); C NMR (CDOD, 300 MHz): 89.96, 17.17, 
18.65, 20.89, 24.52, 33.15, 33.45, 59.58, 61.93, 67.82, 
107.11, 120.66, 123.76, 124.98, 125.80, 128.68, 144.80, 
144.96, 150.72, 154.60; FAB MS (M+H) 703; HRMS M" 
701.4120 (calc for CHNO, 701.4152). 
Gadolinium (III) complex of 4,5-diethyl-10,23-dimethyl 
9,24-bis (3-hydrozypropyl)-16,17-(3-hydroxypropylory)- 
13,20,25,26,27-pentaazapentacyclo 20.2.1.1.1'0' 
heptacosa- 1,3,5,7,9,11 (27),12,14(19), 15,17,20,22(25), 
23-tridecaene. 7, FIG. 7B. IGdB2T2Txp). A mixture of 
4,5-diethyl-10,23-dimethyl-9,24-bis(3-hydroxypropyl)- 
16,17-bis(3-hydroxypropyloxy)-13,20,25,26,27-pentaazap 
entacyclo (20.2.1.1.1.0', heptacosa- 3,5,8,10,12, 
14(19), 15,1720, 22.24-undecaene 7 (1.52g, 0.002 mol), 
gadolinium (III) acetate tetrahydrate (2.64 g, 0.007 mol), 
and triethylamine (ca. 1 mL) in 2 L of methanol was heated 
to reflux under air for 3.5-4 hours. The dark green reaction 
was cooled to room temperature and the solvent removed 
under reduced pressure. Dichloromethane, containing 2% 
methanol, was added to the resulting green solid to form a 
slurry and was filtered to wash away some red colored 
impurities (incomplete oxidation products). The complex 
was then washed through the filter with methanol to leave 
behind some excess gadolinium salts on the filter. The 
methanol was reduced to a small volume on a rotary 
evaporator and then a small amount of silica gel was added. 
The rest of the methanol was removed carefully under 
reduced pressure and the complex/silica gel mixture dried 
under vacuum for several hours. The silica mixture was 
placed on top of a silica gel column and eluted with CHCla 
containing increasing concentrations of methanol (5-100%). 
Fractions containing the complex were collected and the 
solvent removed under reduced pressure. The complex was 
further purified by passing it through a plug of neutral 
alumina using 1:1 CHCl/methanol as the eluent. The final 
column was used to remove any remaining free gadolinium 
salts. The complex was recrystallized from methanol/diethyl 
ether to yield 0.92 g of dark green powder (44%): UV/vis 
nm (CHOH) 414, 474, 738, (H2O) 417, 469, 740; 
FAB MS (M+H) 855; HRMS, (M), 854.2995 (calc for 
CHNO'Gd, 854.3002). 
Lanthanum (III) complex of 4,5-diethyl-10,23-dimethyl 
9,24-bis (3-hydroxypropyl)-16,17-(3-hydroxypropyloxy)- 
13,2025,26,27-pentaazapentacyclo)20.2.1.1.1.0') 
heptacosa- 1,3,5,7,9,11 (27),12,14(19), 15,17.20,22(25), 
23-tridecaene. 7, FIG. 7B. LaB2T2Txp). A mixture of 





3,5,8,10,12,14(19), 15, 17.20, 22.24-undecaene 7 (100 mg, 
0.14 mmol), lanthanum (III) nitrate hexahydrate (185 mg, 
0.42 mmol), and triethylamine (5 drops) in methanol (150 
mL) were heated to reflux under air for 16 hours. The dark 
green reaction was cooled to room temperature and the 
solvents removed on a rotary evaporator. The complex was 
dissolved into methanol and filtered through a fine glass frit. 
A small amount of neutral alumina was added and the 
methanol removed under reduced pressure. The alumina/ 
complex mixture was dried under vacuum for several hours 
then placed on top of a neutral alumina column. The column 
was eluted using neat CHCl and CHCl containing increas 
ing concentrations of methanol (5-20%). Fractions contain 
ing the complex were reduced to dryness on a rotary 
evaporator and the resulting green solid recrystallized sev 
eral times from methanol/diethyl ether. A dark green product 
(66 mg) was obtained (50%): UV/vis nm (CHOH) 
4.17, 476, 746; FAB MS (M+H)" 836; HRMS (M+H), 
836.2886 (calc for CHNO'La, 836.2903). 
EXAMPLE 5 
Synthesis of B4T2 TXP: 
1,2-Dihydroxy-4,5-dinitrobenzene. 8, FIG. 8. In a dry 
500 mL round bottom flask, 1,2-dimethoxy-4,5-dinitroben 
Zene (3.2g, 0.12 mmol) 8 was stirred vigorously in 40 mL 
of glacial acetic acid at 30° C. Once a homogeneous solution 
200 mL of 48% HBr was added to the flask and the reaction 
was slowly heated to reflux. The reaction was complete as 
indicated by TLC after 4 hours. The work up involved 
pouring the cooled solution into 800 mL of ice water and 
then extracting the aqueous phase with CHCl (3x150 mL) 
in order to remove any organic impurities. The dinitro 
catechol was extracted out of the aqueous layer with ethyl 
acetate (3x150 mL). The combined ethyl acetate extracts 
were washed with water and brine (3x100 mL), then dried 
over MgSO and concentrated to an orange residue. 
Approximately 100 mL of dichloromethane was added to the 
residue and then placed in the freezer for several hours. The 
light yellow needles that formed were filtered and washed 
with dichloromethane to yield 2.37 g of product (84%). H 
NMR (d-acetone): 83.45 (OH), 7.42 (Ar–H); C NMR 
(d-acetone): 8112.44, 137.00, 149.97, EI MSM 200. 
1,2-Bis(2,3-dihydroxypropyloxy)-4,5-dinitrobensene. 8, 
FIG. 8. 1,2-Dihydroxy-4,5-dinitrobenzene 8 (5.0 g, 22 
mmol) and 1-chloro-2,3-dihydroxypropane (12.1 g, 110 
mmol) were refluxed for 48 hours in a solution of potassium 
hydroxide (4.4 g) in 1-butanol (100 mL) under a nitrogen 
atmosphere. The resulting mixture was concentrated under 
reduced pressure, and the dark residue was partitioned 
between 100 mL of THF and 100 mL of brine/50 mL water 
solution in a 500 mL separatory funnel. The mixture was 
allowed to separate and the aqueous phase was extracted 
with THF (2x100 mL). The combined THF extracts were 
washed with brine (2x50 mL), dried over MgSO and 
concentrated to an oily residue. Here, CHCl was added 
very carefully to insure precipitation of the crude product. 
After stirring for 15 minutes, the suspension was filtered 
with a medium glass fritted funnel and air dried for several 
minutes. The orange solid was taken up in 120 mL of CHCI 
and 80 mL of diethyl ether at reflux and hot filtered to 
remove some impurities. The crude product was dissolved in 
a mixture of acetone and methanol (sonication may be 
required), then 6 grams of deactivated silica gel was added 
to the orange solution. The slurry was concentrated to 












The orange solid was loaded on a packed deactivated silica 
gel column. The column was eluted starting with neat CHCl 
followed by CHCl with increasing concentration of metha 
nol (0–10%). After a bright yellow impurity (monoalkylated 
product) was removed a colorless product began to elute 
(using 8-10% methanol in CHCl eluents). Conversely, on 
TLC the product will elute faster than the bright yellow 
monoalkylated product. The purified dialkylated tetrahy 
droxy product can be recrystallized from acetone/diethyl 
ether to yield 2.60 grams (30%) of alight yellow fluffy solid. 
H NMR (d-acetone): 82.95 (bs, 4 H, OH), 3.69 (d, 4H, 
OCHCH(OH)CHOH), 4.06 (p, 2 H, OCHC 
H(OH)CHOH), 4.24-4.35 (m, 4 H, OCHCH(OH)C 
HOH), 7.72 (s, 2 H, Ar-H); 'CNMR (d-acetone): 863.55, 
70.89, 72.53, 109.99, 137.22, 152.77. CI MS 349. 
1,2-Diamino-4,5-bis((2,3-dihydroxypropyl)oxy)benzene. 
8, FIG. 8. The diamine was obtained by reduction of the 
corresponding 1,2-bis((2,3-dihydroxypropyl)oxy)-4,5-dini 
trobenzene (0.30 g, 0.86 mmol) with hydrazine hydrate (1 
mL) and 10% palladium on carbon (50 mg) in 40 mL 
refluxing absolute ethanol. The resulting brown suspension 
bubbled for approximately 15-20 minutes and then turned 
colorless after 1 hour. At this point the reduction was 
deemed complete as judged by TLC (Rf-0.63, 100% metha 
nol). The reaction solution was hot filtered through celite 
into a dry flask, covered with aluminum foil, and then 
concentrated to a light yellowish oil. The diamine was taken 
to the next step without further purification. For B4 diamine: 
"H NMR (CDOD): 8 3.54-3.58 (m, 4 H, OC 
HCH(OH)CHOH), 3.80–3.85 (m, 6 H, OCHCH(OH)C 
HOH), 6.39 (s, 2 H, Ar-H); C NMR (CDOD): 8 64.27, 
71.88, 73.22, 107.61, 130.31, 143.74. 
4,5-Diethyl-9,24-bis(3-hydroxypropyl)-16, 17-bis( 2,3- 
dihydroxypropyl)oxy)-10,23-dimethyl-13,20,25,26,27-pen 
taazapentacyclo[20.2.1.1.1.0', 'heptacosa- 3,5,8,10, 
12, 14(19), 15, 17.20,22,24-undacaene. sp B4T2 TXP8, 
FIG.8. 2,5-Bis(5-formyl-3-hydroxypropyl-4-methylpyrrol 
2-yl)methyl-3,4-diethylpyrrole (336 mg, 0.70 mmol) and 
1,2-diamino-4,5-bis((2,3-dihydroxypropyl)oxy)benzene (ca 
223 mg, 0.77 mmol) were placed in a 1 L round bottom flask 
with 600 mL of toluene and 175 mL of methanol. The 
solvents were purged with nitrogen prior to use. Concen 
trated HCl (ca 3 drops) was added and the reaction heated to 
reflux under nitrogen. After one hour the reaction was cooled 
to room temperature and the solvent removed under reduced 
pressure until the dark brown product precipitated. The 
remainder of the solvent was decanted off and the product 
dried in vacuo. The product was used in the next step 
without further purification. 
Gadolinium (III) complex of 4,5-Diethyl-9,24-bis(3-hy 
droxypropyl)- 16,17-bis(2,3-dihydroxypropyl)oxy)-10,23 
dimethyl- 13.20,25,26,27-pentaazapentacyclo[20.2.1.1 
6.1.0'']heptacosa- 1,3,5,7,9,11(27), 12,14(19), 15, 17, 
20,22(25).23-tridecaene (GdB4T2Txp). 8, FIG. 8. Two 
identical reactions containing a mixture of reduced B4T2 
texaphyrin ligand, 4,5-Diethyl-9,24-bis(3-hydroxypropyl)- 
16,17-bis((2,3-dihydroxypropyl)oxy)-10,23-di methyl-13, 
20,25,26,27-pentaazapentacyclo[20.2.1.1.1.0'' 
heptacosa- 3,5,8,10,12,14(19), 15, 17,2022,24-undecaene, 
(0.75 g, 0.001 mol), gadolinium (III) acetate tetrahydrate 
(1.19 g, 0.003 mol), and triethylamine (ca 1 mL) were heated 
at reflux under air in 750 mL of absolute methanol. After 
heating for 17 hours the reactions were cooled slightly and 
air bubbled through the reaction mixture for several minutes. 
The reactions were then heated to reflux again. After heating 
for a total of 21 hours the reactions were cooled to room 
temperature, the solvent removed on a rotary evaporator, and 
5,569,759 
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the dark green products combined and dried in vacuo for 
several hours. The metal complex was dissolved into 100 
mL of methanol and 6-8 grams of deactivated silica gel was 
added. (The silica gel was deactivated by adding a mixture 
of 6 mL water in 20 mL of methanol to 100 g of silica gel. 
After thorough mixing, the silica gel was allowed to air dry 
for 12 hours before bottling). The solvent was carefully 
removed on a rotary evaporator and the silica/complex 
mixture dried in vacuo for one hour. The complex was 
loaded onto a prepacked column of deactivated silica gel (5 
cm length}x3.5 cm diameter) and eluted with chloroform 
containing increasing amounts of methanol (0-80%). Frac 
tions containing the complex were collected and concen 
trated to dryness. The green complex was further purified by 
recrystallization from methanol/anhydrous ethyl ether. 480 
mg of product was obtained from the two combined reac 
tions (25%). For the complex: UV/vis, , nm (CHOH) 
415, 474, 740; FAB MS (M+H) 887; HR MS (M+H)" 
887.2977 (calc for CHNOGd, 887.2981). 
EXAMPLE 6 
Further derivatives of Texaphyrin. 
Intermediates hydroxylated in various positions can be 
combined to effect the synthesis of a number of compounds. 
For example, the B4 TXP derivative is synthesized by 
reacting the intermediate compound 6 from FIG. 6 with 
compound 8 of FIG.8. This constructs a molecule without 
hydroxyl groups on the tripyrrole moiety but with 4 
hydroxyl groups on the benzene ring moiety. 
The molecule T2 TXP is synthesized by reacting inter 
mediate 7 in FIG. 7 with 4,5-dimethyl-1,2-phenylenedi 
amine to yield a texaphyrin derivative with two hydroxyls 
on the tripyrrole portion of the molecule and no hydroxyl 
substituents on the benzene ring. 
A heptahydroxylated target B4T3 TXP is obtained by 
using the appropriate derivative 3-hydroxypropyl-4-meth 
ylpyrrole of the pyrrole (structure 7 of FIG. 7) to make the 
trihydroxylated tripyrrole precursor which is then reacted 
with compound 8 of FIG. 8. 
FIGS. 11A-11C, 12-14, 15A-17B, 18, 19A and 19B 
provide specific examples of how one skilled in the art could 
extend and refine the basic synthetic chemistry outlined in 
this application so as to produce other hydroxylated texa 
phyrins equivalent in basic utility to those specifically 
detailed in the examples. FIGS. 11A-11C summarizes the 
synthesis of polyether-linked polyhydroxylated texaphyrins. 
FIG. 12 summarizes the synthesis of catechol (i.e. benzene 
diol) texaphyrin derivatives bearing further hydroxyalkyl 
substituents off the tripyrrane-derived portion of the mac 
rocycle. FIG. 13 provides an example of a saccharide 
substituted texaphyrin in which the saccharide is appended 
via an acetal-like glycosidic linkage. FIG. 14 summarizes 
the synthesis of a doubly carboxylated texaphyrin system in 
which the carboxyl groups are linked to the texaphyrin core 
via aryl ethers or functionalized alkyl substituents. The 
products of this scheme, compounds 14 and 14 could be 
converted to various esterified products wherein the ester 
linkages serve to append further hydroxyl-containing sub 
stituents. FIGS. 15A and 15B summarizes the synthesis of 
polyhydroxylated texaphyrin derivatives via the use of sec 
ondary amide linkages. FIGS. 16A and 16B summarizes the 
synthesis of another set of polyhydroxyl substituted texa 
phyrin derivatives using similar amide bonds as in FIGS. 
15A and 15B. FIGS. 17A and 17B summarizes the synthesis 












ride moieties are appended via amide bonds. FIG. 18 sum 
marizes the synthesis of polyhydroxylated texaphyrin 
derivatives containing branched polyhydroxyl (polyol) sub 
units appended to the texaphyrin core via aryl ethers. FIGS. 
19A and 19B summarizes how similar polyol subunits may 
be appended via ester linkages. 
EXAMPLE 7 
Characterization of new derivatives. 
New texaphyrin derivatives may be characterized fully 
using normal spectroscopic and analytical means, including, 
X-ray diffraction methods. A complete analysis of the optical 
properties may be made for new systems under a range of 
experimental conditions including conditions designed to 
approximate those in vivo. Detailed analyses, including 
triplet lifetime and singlet oxygen quantum yield determi 
nations may be made. The objective is to obtain a complete 
ground and excited state reactivity profile for each new 
texaphyrin produced. Questions such as when singlet oxy 
gen production is maximized, how the quantum yield for its 
formation is influenced by the position of the lowest energy 
(Q-type) transition, whether aggregation is more prevalent 
in certain solvents or in the presence of certain biologically 
important components (e.g. lipids, proteins, etc.), and, 
finally, whether significant differences in in vitro optical 
properties are derived from the use of elaborated texaphyrins 
bearing cationic, anionic, or neutral substituents may be 
answered. 
With newly prepared complexes, screening experiments 
are carried out. Standard in vitro protocols are used to 
evaluate the in vitro photo-killing ability of the texaphyrin 
derivatives in question. For instance, the texaphyrin com 
plexes of choice may be administered in varying concen 
trations to a variety of cancerous cells and the rate of cell 
replication determined both in the presence and absence of 
light. Similarly, texaphyrin complexes of choice may be 
added to standard viral cultures and the rate of viral growth 
retardation determined in the presence and absence of light. 
A variety of solubilizing carriers will be used to augment the 
solubility and/or monomeric nature of the texaphyrin pho 
tosensitizers and the effect, if any, that these carriers have in 
adjusting the biodistribution properties of the dyes will be 
assessed (using primarily fluorescence spectroscopy). 
Appropriate control experiments are carried out with normal 
cells so that the intrinsic dark and light toxicity of the 
texaphyrins may be determined. 
From a generalized set of in vitro experimental proce 
dures, a clear picture of the photodynamic capabilities of the 
texaphyrin derivatives will emerge. Preliminary toxicity and 
stability information will result from the in vitro experi 
ments. Particular questions of interest include the texaphyrin 
derivatives half life under physiological conditions, whether 
the nature of the central metal influences stability and 
whether the central cation is affecting cytotoxicity. As dis 
cussed in papers published by the present inventors,' it is 
not possible to remove the larger bound cations (e.g. Cd' or 
Gd") by simple chemical means (Zn' however appears to 
"fall out” with ease). Preliminary results indicate that the 
lanthanum(III)-containing texaphyrin complex is not appre 
ciably cytotoxic. Nonetheless, the question of intrinsic tox 
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icity is one of such central importance that the cytotoxicity 
of all new systems should be screened in vitro and, where 
appropriate, further in vivo toxicity studies carried out. 
EXAMPLE 8 
Viral Inactivation by Texaphyrin Macrocycles. 
One aspect of the utility of the present invention is the use 
of complexes described herein for photon-induced deacti 
vation of viruses and virally infected or potentially infected 
eucaryotic cells. The general photodeactivation method used 
in this example was developed by the Infectious Disease and 
Advanced Laser Applications Laboratories of the Baylor 
Research Foundation, Dallas, Tex. and is a subject of U.S. 
Pat. No. 4,878,891 which is incorporated herein by refer 
C. 
The efficiency of some of the porphyrin-like macrocycles 
in photosensitized inactivation of Herpes Simplex Virus 
Type 1 (HSV-1) and of human lymphocytes and monocytes, 
both peripheral mononucleated vascular cells (PMC) and 
cellular hosts of HIV-1 has been initiated. Previous studies 
of vital inactivation using the macrocyclic photosensitizers 
dihematoporphyrin ether (DHE) or hematoporphyrin deriva 
tive (HPD) have shown that with the porphyrins, only those 
viruses studied which are enveloped or possess a membra 
neous coat are inactivated. The enveloped viruses studied 
include HSV-1, cytomegalovirus, measles virus', and the 
human immunodeficiency virus HIV-1'. 
The photosensitized inactivation of Herpes Simplex 
Virus, Type 1 (HSV-1) was investigated in culture medium 
using various macrocycles. Results are listed in Table 1. 
TABLE 
Herpes Simplex Virus I Inactivation with 
Expanded Porphyrin Macrocycle Complexes 
Survival Wiral 
Complex** Conc. (M) Infectivity 








*All light irradiation at A. max absorption and to give a light fluence of 10 
Jicm 
**Structural formulas in FGS. 1A, 1B, 5A and 5B. 
The two cadmium-containing macrocycles (1, 5 (where 
M is Cd)), at concentrations of 20 uM demonstrated as90% 
viral inactivation as judged by vital plaque assay. 
The macrocycle photosensitizing studies employed envel 
oped HSV-1 as the model for screening based on its ease of 
propagation and assessment of infectivity in cell culture. The 
screening procedure for photoinactivation of HSV-1 was 
similar to the methods previously described." Essentially, 
selected macrocycles at different concentrations were added 
to a cell-free suspension of 10 PFU/ml of HSV-1. The viral 
suspensions were irradiated at the optimal absorption wave 
length of the selected dye at different light-energy densities. 
Controls consisted of (1) nonirradiated virus, (2) virus 
irradiated in the absence of macrocycle, and (3) virus treated 
with selected concentrations of macrocycle and maintained 
in the dark. All samples were then assessed for viral infec 












Viral suspensions were serially diluted and subsequently 
absorbed onto Vero cell monolayers for 1% hours at 37° C. 
An overlay medium was added and the cells incubated at 37 
C. for 3-4 days. The overlay medium was then removed, the 
monolayers fixed with methanol and tinctured with Giemsa, 
and individual plaques counted under a dissecting micro 
scope. Uninfected cell cultures also were exposed to the 
macrocycle complexes to rule out direct cytotoxic effects. 
The inactivation of PMC's in the absence and presence of 
light after exposure to concentrations of complex 1 in 
whole human plasma ranging from 0.015 to 38 uM is shown 
in FIGS. 9 and 10. Inactivation was judged by mitogenic 
assay. Toxicity onset with 1 (see FIG. 1B) and 2 (M=Zn" 
+, see FIG. 2B) in the absence of light was between 0.15 and 
1.5uM (FIG. 9). As shown by mitogenic assay in FIG. 10, 
aerobic photosensitization of cells exposed to 1 at 0.15uM 
concentration and 20 joules/cm’ of 770 nm wavelength light 
caused significant inhibition of the cellular division of 
PMC's. Moderate increase in either photosensitizer concen 
tration or light dosage is expected to result in essentially 
complete cellular inactivation. 
Results indicate that the expanded porphyrin-like macro 
cycles should be efficient photosensitizers for free HIV-1 
and infected mononuclear cells. Altering the polarity and 
electrical charges of side groups of these macrocycles is 
anticipated to alter the degree, rate, and perhaps site(s) of 
binding to free enveloped viruses such as HIV-1 and to 
virally-infected peripheral mononuclear cells, thus modulat 
ing photosensitizer take-up and photosensitization of leuke 
mia or lymphoma cells contaminating bone-marrow as well. 
EXAMPLE 9 
Antibody Conjugates 
Radioisotopes play a central role in the detection and 
treatment of neoplastic disorders. Improving their efficacy in 
medical applications involves attaching radioisotopes to 
tumor-directed monoclonal antibodies and their fragments. 
Radiolabeled antibodies could therefore serve as "magic 
bullets' and allow the direct transport of radioisotopes to 
neoplastic sites thus minimizing whole body exposure to 
radiation.' The use of bifunctional metal chelating 
agents in radioimmunodiagnostics (RID) and therapy (RIT) 
is most closely related to the present invention. 
Bifunctional metal chelating agents for use in antibody 
conjugate-based treatment and diagnostic applications must 
1) have functional groups suitable for conjugation to the 
antibody, 2) form covalent linkages that are stable in vivo 
and which do not destroy-the immunological competence of 
the antibody,3)be relatively nontoxic, and 4) bind and retain 
the radiometal of interest under physiological conditions.' 
191 The last of these conditions is particularly severe. The 
potential damage arising from "free' radioisotopes, released 
from the conjugate, can be very serious. On the other hand, 
only nanomole concentrations of isotopes, and hence ligand, 
are generally required for RID and RIT applications, so that 
the concerns associated with intrinsic metal and/or free 
ligand toxicity are somewhat relaxed. 
For the purposes of imaging, an ideal isotope should be 
readily detectable by available monitoring techniques and 
induce a minimal radiation-based toxic response. In practice 
these and other necessary requirements implicate the use of 
a Y-ray emitter in the 100 to 250 KeV range, which possesses 
a short effective half-life (biological and/or nuclear), decays 
to stable products, and, of course, is readily available under 
clinical conditions. '7' To date, therefore, most attention 
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has focused on 'I (t=193h), 'I(t=13 h), ''"Tc(t, 
2=6.0h), ''Ga(t=78h), and 'In(t=67.4 h) which come 
closest to meeting these criteria.' Each of these enjoys 
advantages and disadvantages with respect to antibody 
labeling for RID. 'I and 123I, for instance, are easily 
conjugated to antibodies via electrophilic aromatic substi 
tution of tyrosine residues.' The metabolism of 'I or 'I 
labeled proteins, however, produces free radioactive iodide 
anion and as a result can lead to a fair concentration of 
radioactivity at sites other than those targeted by the anti 
body-derived "magic bullet”.' The half-lives of both 131I 
and 1231 are relatively inconvenient for optimal use, being 
too long and too short, respectively, and the fact that 'I is 
also a B emitter.''"Tc,7Ga and 'In all suffer from the 
disadvantage that they cannot be bound directly to the 
antibody in a satisfactory fashion and require the use of a 
bifunctional conjugate. The chemistry of such systems is 
furthest advanced in the case of '"Te, and a number of 
effective ligands, are now available for the purpose of '"Tc 
administration.''''This radioisotope has a very short 
half-life which makes it technically very difficult to work 
with. Both 'Ga and illin have longer half-lives and possess 
desirable emission energies. Both are "hard” cations with 
high charge density in their most common trivalent forms. 
No suitable ligands exist for either 'In or Ga" which 
form stable nonlabile complexes and which might be suit 
able for radioimmunological applications. As described else 
where herein texaphyrin forms a kinetically and hydrolyti 
cally stable complex with In". Such aligand system may be 
elaborated and serve as the critical core of a bifunctional 
conjugate for use in 'In-based RID. 
Many of the same considerations hold true for radioiso 
tope-based therapy as do for radioisotope-based diagnostics: 
An ideal isotope must also be readily available under clinical 
conditions (i.e. from a simple decay-based generator).' 
possess areasonable half-life (i.e. on the order of 6 hours to 
4 weeks), and decay to stable products. In addition, the 
radioisotope must provide good ionizing radiation (i.e. in the 
300 KeV to 3 MeV range). A number of Bemitters, including 
'I, are currently receiving attention as possible candidates 
for RIT. Among the more promising, are Re (t=90 h, 
Cu (t=58.5 h), and 'Y (t=65 h). Of these, 'Y is 
currently considered the best,' with an emission energy 
of 2.28 MeV, it is calculated to deliver roughly 3 to 4 times 
more energy (dose) to the tumor per nanomole than either 
'Re or 'Cu. Good immuno-compatible chelands exist for 
only Re and 'Cu, the former may be attached using the 
same ligands as were developed for '"Tc,' and the latter 
via the rationally-designed activated porphyrins developed 
by Prof. Lavallee of Hunter College and the Los Alamos 
INC-11 team.' Further benefits should be derived from a 
bifunctional conjugate which is capable of forming stable, 
nonlabile complexes with 'Y' (which cannot be done with 
porphyrins). The texaphyrin ligand of the present invention 
not only forms stable complexes with In" but also binds Y." 
effectively. A texaphyrin-type bifunctional conjugate may be 
prepared for use in 'In-based RID and in Y-based RIT. 
Both Y and 'In could conceivably be attached to an 
antibody of choice using a functionalized texaphyrin. The 
Y" and In" complexes of texaphyrin are formed rapidly 
(insertion and oxidation times are less than 3 hours) from the 
methylene-linked reduced precursor, and are hydrolyrically 
stable in 1:1 methanol-water mixtures (the half-lives for 
decomplexation and/or ligand decomposition exceed 3 
weeks in both cases. 
The hydroxy-substituted texaphyrin molecules of the 











tional chelating agents in antibody conjugate-based treat 
ment since they have functional groups suitable for conju 
gation to the antibody, they form covalent linkages that are 
stable in vivo which do not destroy the immunological 
competence of the antibody, they are relatively nontoxic, 
and they are readily soluble in a physiological environment. 
A further advantage of these soluble texaphyrins is that 
many of these would be suitable for further functionaliza 
tion. Treatment of carboxylated texaphyrins with thionyl 
chloride or p-nitrophenol acetate would generate activated 
acyl species suitable for attachment to monoclonal antibod 
ies or other biomolecules of interest. Standard in situ cou 
pling methods (e.g. 1,1'-carbonyldiimidazole (CDI)'') 
could be used to effect the conjugation. The ability to attach 
and deliver a potent photosensitizer directly to a tumor locus 
could have tremendous potential benefit in the treatment of 
neoplastic disorders. In addition, this approach will allow a 
variety of useful radioisotopes such as 'Y and 'In to be 
attached to a monoclonal antibody. 
The hydroxy-substituted texaphyrin molecules of the 
present invention are also suited for delivering radioactivity 
to a tumor on their own since they chelate radioisotopes and 
have intrinsic biolocalization selectivity. 
EXAMPLE 10 
Magnetio Resonance Imaging Enhancement, Imaging 
with B2T2 in vivo. 
In many respects the key to cancer control lies in early 
detection and diagnosis as it does in subsequent therapeutic 
management. New techniques which allow neoplastic tissue 
to be observed and recognized at an early stage of devel 
opment thus have a critical role to play in the battle against 
these disorders. One such promising technique is magnetic 
resonance imaging (MRI).' Although quite new, this 
noninvasive, apparently innocuous method, is now firmly 
entrenched as a diagnostic tool of prime importance, 
complementing or, in some cases, supplanting computer 
assisted X-ray tomography as the method of choice for solid 
tumor detection. 
The physical basis of current MRI methods has its origin 
in the fact that in a strong magnetic field the nuclear spins 
of water protons in different tissues relax back to equilibrium 
at different rates. When these local, tissue-dependent relax 
ation differences are large, tissue differentiation can be 
effected. Paramagnetic compounds, containing one or more 
unpaired spins, enhance the relaxation rates for the water 
protons in which they are dissolved.' The extent of this 
enhancement is termed relaxivity. At present, only one 
paramagnetic MRI contrast agent is in clinical use, the 
bis(N-methyl-glucamine) salt of Gd(III) diethylenetriamine 
pentaacetate, (MEG)(Gd(DTpA)(HO) (c.f. structure 
10)''' marketed by Berlex Laboratories. This dianionic 
complex localizes selectively in extracellular regions, and is 
being used primarily in the visualization of the capillary 
lesions associated with cerebral tumors.'' 
Considerable effort has been devoted to the development 
of new potential MRI contrast agents.' Most of this work 
has centered around preparing new complexes of 
Gd(III), 156-164.171-172 
The emphasis on Gd(III) salts stems from the fact that this 
cation, with 7 unpaired f-electrons, has a higher magnetic 
moment than other paramagnetic cations such as Fe(III) and 
Mn(II). ''Thus complexes of Gd(III) would be expected 
to be superior relaxation agents than those derived from 
Mn(II) or Fe(III). In addition, both iron and, to a lesser 
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extent, manganese are sequestered and stored very effi 
ciently in humans (and many other organisms) by a variety 
of specialized metal-binding systems.' Moreover both iron 
and manganese are capable of existing in a range of oxida 
tion states and are known to catalyze a variety of deleterious 
Fenton-type free-radical reactions.'" Gadolinium(III), 
which suffers from neither of these deficiencies, thus appears 
to offer many advantages. As is true for Fe(III) and Mn(II), 
the aqueous solution of Gd(III) is too toxic to be used 
directly for MRI imaging at the 0.01 to 1 mM concentrations 
required for effective enhancement.' Hence the empha 
sis is on developing new agents which, as is true for DTPA, 
form hydrolytically stable complexes in vivo with Gd(III) 
and/or other paramagnetic cations. A number of Such 
ligands, including the very promising DOTA''' and 
EHPG'''' systems, are now known (c.f. reference 140 for 
an extensive review). In almost all cases, however, reliance 
is made on the same basic philosophical approach. Specifi 
cally, for Gd(III) binding, carboxylates, phenolares, and/or 
other anionic chelating groups are being used to generate 
intrinsically labile complexes of high thermodynamic sta 
bility in the hope that such high thermodynamic stability 
will translate into a kinetic stability that is sufficient for in 
vivo applications. Little effort is currently being devoted to 
the preparation of nonlabile Gd(III) complexes that would in 
and of themselves enjoy a high kinetic stability. The problem 
seems to be quite simply that such systems are hard to make. 
For instance, unlike the transition metal cations which are 
bound well to porphyrins (a synthetically versatile ligand 
which is readily subject to modification and which, at least 
for Mn(III)TPPS'', and other water soluble analogues, 
''' shows good relaxivity and good tumor localizing 
properties), Gd(III) forms only weak and/or hydrolytically 
unstable complexes with porphyrins,''''' although 
other simple macrocyclic amine- and imine-derived 
ligands'777 will support stable complexes with certain 
members of the lanthanide series and do show some prom 
ise, as yet unrealized, of acting as supporting chelands for 
Gd(III)-based MRI applications. 
According to the present invention nonlabile Gd(III) 
complexes of hydroxy-substituted texaphyrins prove to be 
useful contrast agents for MRI applications. Hydroxy-sub 
stituted texaphyrins are capable of stabilizing complexes 
with a variety of di- and trivalent cations including Cd', 
Hg, Lu", Gd", and La". Such complexes are particu 
larly soluble in physiological environments. 
Magnetic Resonance Imaging with B2T2 in vivo 
The T2B2 gadolinium complex showed low toxicity and 
good tissue selectivity in magnetic resonance imaging 
enhancement. 
Imaging: Scanning was performed using a circumferential 
transmit/receive coil (Medical Advances, Milwaukee, Wis.) 
in the bore of a 1.5 Tesla Signa scanner (GE Medical 
Systems, Milwaukee, Wis.). Normal male Sprague-Dawley 
rats (n=5) weighing from 280-320 grams and rats bearing 
subcutaneously implanted methylcholanthrene-induced fib 
rosarcomas in their left flanks (n=4) were studied. Tumor 
size at the time of the study ranged from 2.5 to 3.5 cm in 
widest diameter. The rats were anesthetized with 90 mg/kg 
of ketamine (Vetalar, Aveco Corporation, Fort Dodge, IO) 
and 10 mg/kg of xylazine (Rompun, Mobay Corporation, 
Shawnee, Kans.) intraperitoneally. Following the insertion 
of an intravenous catheter in the tail vein, each animal was 
placed in supine (normal rats) or prone (tumor-bearing rats) 
position in the center of the coil. Coronal and axial T1 
weighted images were obtained of each animal using a spin 













msec, TE 15 msec, slice thickness 5 mm, matrix 128x256, 
field of view 10 cm, 4 excitations and no phase wrap. Next, 
17 umol/kg of the Gd(III)texaphyrin complex dissolved in 
normal saline was infused at a rate of 0.25 ml/min intrave 
nously and repeat images were obtained at 10-15 minutes 
post contrast. One tumor-bearing rat was studied at 6 and 28 
hours post-contrast. All tuning parameters and the rats' 
positions were kept identical in the pre and post contrast 
SCaS 
Image Analysis: Operator defined regions of interest 
(ROI) measurements were made on axial slices of all pre and 
10-15 minutes post contrast studies. Regions in which 
measurements were made included the right lobes of the 
livers and the whole kidneys in the normal rats and the 
whole tumor in tumor-bearing rats. In addition, large ROI's 
of background air were measured for standardization pur 
poses. Standardized signal intensities (SSI) were calculated 
as follows: signal intensity (SI) of organ/SI air. An unpaired 
Student's test was used to compare pre contrast and post 
contrast SSIs. 
Toxicity: At 24 hours, there were no deaths in the mice 
injected i.p. although those receiving the highest dose (312.5 
umol/kg) appeared lethargic. Autopsies of two mice from 
each dosage group revealed some edema and pallor of the 
liver and kidneys in the two groups receiving the highest 
doses (312.5 and 156.3 umol/kg). Autopsies from the 
remaining groups were normal. At 48 hours, the remaining 
mice (n=3 in each dosage group) in the two highest dosage 
groups died. The animals in the three lower dosage groups 
demonstrated no morbidity. There was no mortality or 
evidence of morbidity in the rats during the month of 
observation after scanning. 
Enhancement: Liver SSI increased by 81.7% (p<0.001), 
kidney by 114.9% (p < 0.001) and tumor by 49.7% (p < 
0.02) from pre to 10-15 minutes post contrast. There was no 
significant difference in enhancement between the right and 
left lobe of the liver and between the two kidneys. Pre 
contrast, tumor parenchyma appeared homogeneous and of 
an intensity similar to adjacent muscle. Post contrast, tumor 
tissue demonstrated a mottled pattern of enhancement and 
was easily distinguished from adjacent tissues. The MRI 
appearance reflected the heterogeneous appearance of the 
tumor grossly which consists of necrotic tissue surrounded 
by viable stroma. In addition, in the one animal studied at 6 
and 28 hours post contrast, there was visible tumor enhance 
ment throughout the study period. The pattern of enhance 
ment, however, changed over time, with enhancement start 
ing at the edges of the tumor initially and including the 
center by 28 hours. 
These results show that the T2B2 gadolinium complex is 
an hepatic, renal and tumor-specific contrast agent. The 
agent was found to have relatively low toxicity in rodents. 
Intravenous administration resulted in statistically signifi 
cant hepatic, renal and tumor enhancement in rats within 
10-15 minutes with persistence of tumor enhancement for 
up to 28 hours. The early enhancement of tumor edges may 
represent contrast localization in areas of viable tumor. The 
later appearance of the tumor probably was caused by 
passive diffusion of some of the agent into central necrotic 
areas. It is unclear whether a selective transport or passive 
diffusion mechanism is responsible for initial tumor 
enhancement with GD(III)texaphyrin and whether intracel 
lular binding to peripheral-type benzodiazepene receptors 
occurs. The tumor could be differentiated from adjacent 
tissues for up to 28 hours. 
The chemical properties of this texaphyrin class of mac 
rocyclic ligands can be varied by peripheral substitution, 
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which would allow biological properties to be optimized in 
terms of biodistribution, pharmacokinetics and toxicity. 
Magnetic Resonance Imaging of Atheroma. 
The gadolinium complex of B2T2 (4,5-diethyl-10,23 
dimethyl-9,24-bis(3-hydroxypropyl)-16,17-(3-hydroxypro 
pyloxy)- 13.20,25,26,27-pentaaza pentacyclo[20.2.1.1.1 
11.0''']heptacosa- 1,3,5,7,9,11(27),12,1 4(19), 15,17.20, 
22(25).23-tridecaene shows accumulation in human 
cadaveric aorta. Two aortas obtained from autopsies were 
examined using magnetic resonance imaging before and 
after incubation in vitro for 15 minutes with the gadolinium 
complex of B2T2. Selective labeling of the endothelial cell 
surface and atheromas plaque relative to surrounding tissue 
was observed. These data indicate that the Gd(III)B2T2 
complex has utility in the non-invasive imaging of 
atheroma. 
Magnetic Resonance Imaging of the Upper GI Tract. The 
gadolinium complex of B2T2 (4,5-diethyl-10,23-dimethyl 
9,24-bis( 3-hydroxypropyl)-16,17-(3-hydroxypropyloxy)- 
13,20,25,2627-pentaaza pentacyclo[20.2.1.1.1.0''' 
heptacosa- 1,3,5,7,9,11(27),12,14(19), 15,1720,22(25),23 
tridecaene shows accumulation in the upper GI tract, 
especially the stomach, as determined by magnetic reso 
nance imaging. 
EXAMPLE 11 
Photodynamic Therapy, In vitro and In vivo Experiments 




1,3,5,7,9,11(27), 12,1 4(19), 15, 17.20,22(25),23-tridecaene 
(LaB2T2) was used at concentrations of 5.0, 1.0 or 0.1 
micromolar in tissue culture medium. The murine mammary 
carcinoma cell line designated EMT-6 was cultured in 
medium containing LaB2T2 for 1 hour or 3 hours in the 
dark. Experimental cultures were irradiated with 10 Joules/ 
cm using an arc lamp with a 750 nanometer band pass filter. 
Cell survival was measured using a cell cloning assay. There 
was no dark toxicity indicating that LaB2T2 had no direct 
toxicity to the cells. Cultures which were irradiated with the 
visible red light showed viabilities of 3%, 50% and 100% for 
concentrations of LaB2T2 of 5.0, 1.0 and 0.1 micromolar 
respectively. The results were similar for 1 and 3 hour 
incubation periods. The results established that LaB2T2 was 
phototoxic to these tumor cells in vitro. 
In vivo experiments. Murine adenocarcinoma cells were 
inoculated into both flanks of Balb/c mice. Four days later, 
palpable tumor masses were present on both flanks of the 
mice. Ten mg/kg of lutetium B2T2 (LuB2T2) in aqueous 
solution was injected IV. Seven hours later, one tumor mass 
was irradiated with 500 Joules of Argon laser light at 746 
nanometers. The unirradiated tumor served as a control. 
Animals were monitored daily and tumor measurements 
were made using calipers. Following a single treatment, 
65% cell kill was estimated based on the reduction in size of 
the treated tumors. No phototoxicity of skin or normal 
tissues surrounding the tumors was observed indicating 
relatively selective uptake of the LuB2T2 in the tumors. This 
experiment established the in vivo photodynamic activity of 
LuB2T2 in vivo. 
The hydroxy-substituted texaphyrins can be conjugated to 
biological molecules, especially proteins of molecular 
weight greater than about 20,000 daltons, e.g. albumin and 













kidneys. A prolonged presence of these complexes in tissue 
may be desirable for photoirradiation purposes. The conju 
gation would be accomplished as described in Example 9 for 
antibody conjugates. 
EXAMPLE 12 
Hydroxy-Substituted Texaphyrins in Magnetic Resonance 
Imaging followed by Photodynamic Therapy for Tumor 
Destruction 
This example describes a use of the present invention of 
hydroxy substituted texaphyrins in the destruction of tumor 
tissue. A detectable metal complex of a water soluble 
hydroxy-substituted aromatic pentadentate expanded por 
phyrin analog retaining lipophilicity, said complex exhibit 
ing selective biolocalization in benign or malignant tumor 
cells relative to surrounding tissue is administered as a first 
agent to a host harboring benign or malignant tumor cells. 
Localization sites in the host are determined by reference to 
the detectable metal. A water soluble hydroxy-substituted 
aromatic pentadentate expanded porphyrin analog-detect 
able-metal complex retaining lipophilicity and having essen 
tially identical biolocalization property and exhibiting the 
ability to generate singlet oxygen upon exposure to light will 
be administered as a second agent. The second agent is 
photoirradiated in proximity to the benign or malignant 
tumor cells, as is using fiber optics, to cause tumor tissue 
destruction from the singlet oxygen produced. The water 
soluble hydroxy-substituted aromatic pentadentate 
expanded porphyrin analog retaining lipophilicity is a 
hydroxy-substituted texaphyrin although one skilled in the 
art can see from the foregoing that substituted sapphyrins, 
pentaphyrins or other macrocyclic ligands capable of chelat 
ing a metal, soluble in aqueous fluids and localizing in a lipid 
rich environment may be of particular value. The detectable 
metal in the first agent is a paramagnetic metal, preferably 
Gd(III) or a gamma emitting metal. The localization sites are 
determined using MRI when a paramagnetic metal is used 
and gamma body scanning when a gamma emitting metal is 
used. The detectable metal in the second agent is a diamag 
netic metal, preferably La(III), Lu(III) or In(III). Texaphy 
rin-metal complexes will be chosen which themselves show 
a high intrinsic biolocalization selectivity for tumors or 
neoplastic tissues. For example, the B2T2 Gd(III) complex 
demonstrates in vivo affinity for tissue high in lipid content, 
atheroma, the liver, kidneys and tumors. When appropriately 
followed by fiber optic photodynamic therapy, cells in the 
atheroma or tumor can be deactivated. 
The hydroxy substituted diamagnetic texaphyrin com 
plexes are good candidates for such biomedical photosen 
sitizers. They are easily available, have low intrinsic cyto 
toxicity, long wavelength absorption, generate singlet 
oxygen, are soluble in physiological environments, have the 
ability to be conjugated to site specific transport molecules, 
have quick elimination, are stable and are easily subject to 
synthetic modification. 
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What is claimed is: 
1. A method for synthesizing an aromatic texaphyrin 
metal complex having at least one hydroxy substituent, the 
method comprising: 
mixing a nonaromatic texaphyrin having at least one 
hydroxy substituent, a metal cation, a Brønsted base 
and an oxidant selected from the group consisting of 
air, oxygen, platinum oxide and 2,3-dichloro-1,4-ben 
Zoquinone, in an organic solvent that dissolyes the 
nonaromatic texaphyrin, and 
stirring at ambient temperature or heating the mixture at 
reflux for at least two hours to form an aromatic 
texaphyrin metal complex having at least one hydroxy 
substituent. 
2. The method of claim 1 wherein the nonaromatic 
texaphrin having at least one hydroxy substituent is pro 
duced by condensation of a diformyltripyrrole having struc 
ture A, and an ortho-phenylenediamine having structure B: 
al., J. Am. Chem. Soc. 1981, 
R4 R. R3 R2 R1 R4 A 
/ \ W \ W \, t 
N N N 
O H H H O 
HN R5 . B 
H2N R5 
where 
Rhd 1,R,R,R, and Rs are independently H, OH, alkyl, 
oxyalkyl, hydroxyalkyl, oxyhydroxyalkyl, monosac 
charide, carboxyalky or carboxyamidealkyl; where at 
least one of R, R2, R2, R, and Rs is oxyhydroxyalky, 
monosaccharide, oxyalkyl, carboxyalkyl, carboxya 
midealkyl or hydroxyalkyl, and the molecular weight 
of any one of R, R2, R., R., or Rs is less than or equal 
to about 1000 daltons. 
3. The method of claim 2 wherein the diformyltripyrrole 
is 2,5-bis(5-formyl-3-hydroxyalkyl-4-alkylpyrrol-2-yl)m- 
ethyl-3,4-dialkylpyrrole and the ortho-phenylenediamine is 
1,2-diamino-4,5-bis(oxyhydroxyalkyl)benzene. 
4. The method of claim 2 wherein the diformyltripyrrole 
is 2,5-bis(5-formyl-3-hydroxyalkyl-4-alkylpyrrol-2-yl)m- 
ethyl)-3,4-dialkylpyrrole. 
5. The method of claim 2 wherein the orthophenylenedi 
amine is 1,2-diamino-4,5-bis(oxyhydroxyalkyl)benzene. 
6. The method of claim 5 wherein the orthophenylenedi 
amine is 1,2-diamino-4,5-bis(2,3-hydroxypropyl)oxyben 
Z. 
7. The method of claim 5 wherein the orthobenylenedi 
amine is 1,2-diamino-4,5-bis(2,3-dihydroxypropyl)oxy) 
benzene. 
8. The method of claim 4 wherein the diformyltripyrrole 
is 2,5-bis(5-formyl-3-hydroxypropyl-4-methylpyrrol-2-yl 
)methyl-3,4-diethylpyrrole. 
9. The method of claim 4 wherein the diformyltripyrrole 
is 2,5-bis(3-ethyl-5-formyl- 4-methylpyrrol-2-yl)methyl)- 
3,4-diethylpyrrole. 













11. The method of claim 1 wherein the oxidant is air and 
the air is saturating the organic solvent. 
12. The method of claim 1 wherein the stirring or heating 
at reflux step is stirring or heating at reflux the mixture for 
at least 24 hours. 
13. The method of claim 1 wherein the organic solvent 
comprises methanol and chloroform. 
14. The method of claim 1 wherein the organic solvent 
comprises methanol and benzene. 
15. The method of claim 2 where 
R, R2, R3, and Ra are independently hydrogen or 
CH2 where n is a positive integer from 1 to about 
10; and 
Rs is hydroxyl, hydroxyalkyl, oxyhydroxyalkyl, carboxy 
alkyl or carboxyamidealkyl. 
16. The method of claim 2 where 
R,R,R, and Ra are independently hydrogen, hydroxyl, 
alkyl, hydroxyalkyl, oxyhydroxyalkyl, carboxyalkyl or 
carboxyamidealkyl, and Rs is H or CH2 where at 
least one of R, R2, R2, and R4 is hydroxyl, hydroxy 
alkyl, carboxyalkyl, carboxyamidealkyl or oxyhy 
droxyalkyl, and 
n is a positive integer from 1 to 10. 
17. The method of claim 2 where 
R, R2, and R are CHCH, R is CH, and Rs is 
OCHCHCHOH. 
18. The method of claim 2 where 
R is (CH2)CHOH, R and R are CHCH, and R and 
Rs are CH 
19. The method of claim 2 where 
R is (CH2)2CH2OH, R2 and R are CHCH, R is CH, 
and Rs is OCH2CH2CH2OH. 
20. The method of claim 2 where 
R, R2, and R are CHCH, R is CH, and Rs is 
OCHCHOHCHOH. 
21. The method of claim 2 where 
R is (CH2)CH-OH, R and R are CHCH, R is CH, 
and R is OCHCHOHCHOH. 
22. The method of claim 2 where 
R is (CH2)CHOH, R is CHCH-OH, R is CHCH 
R is CH, and R is OCHCHOHCHOH. 
23. The method of claim 2 wherein the oxyhydroxyalkyl 
is Co-Ho-1-2.O.Oy or OCo-Ho-1-2.O.O. where 
n is a positive integer from 1 to 10; 
X is Zero or a positive integer less than or equal to n; and 
y is Zero or a positive integer less than or equal to 
((2n+1)-2x). 
24. The method of claim 2 wherein the oxyhydroxyalkyl 
or monosaccharide is CH2--OR OCH2-1- 
aOR or (CH2)COR where 
n is a positive integer from 1 to 10, 
y is Zero or a posimive integer less than ((2n+1)-q), 
q is zero or a positive integer less than or equal to 2n+1, 
R" is independently H, alkyl, hydroxyalkyl, monosaccha 
ride, Con-whom -1-2O.O., O2CCon-w) Hon-1)- 
2w)O.O. or N(R)OCCo-Ho-1-2O, O, where 
m is a positive integer from 1 to 10, 
w is zero or a positive integer less than or equal to m, 
Z is zero or a positive integer less than or equal to 
((2m+1)-2w), 
R is H, alkyl hydroxyalkyl, or C.H.O.R, where 
m is a positive integer from 1 to 10, 
z is zero or a positive integer less than ((2m+1)-r), 




R’ is independently H, alkyl, hydroxyalkyl, or 
monosaccharide. 
25. The method of claim 2 wherein the carboxyamid 
ealkyl is (CH),CONHR'. O(CH),CONHR, 
(CH),CON(R), or O(CH),CON(R), where 
n is a positive integer from 1 to 10, 
R" is independently H, alkyl, hydroxyalkyl, monosaccha 
ride, Con-wic(2n+1)-20-O- O2CCon-Hicon-O.O. 
or N(R)OCCH22O, O, where 
m is a positive integer from 1 to 10, 
w is zero or a positive integer less than or equal to m, 
Z is zero or a positive integer less than or equal to 
((2m+1)-2w), 
R is Halkyl, hydroxyalkyl, or CH2 OR, where 
m is a positive integer from 1 to 10, 
z is zero or a positive integer less than ((2m+1)-r), 
ris Zero or a positive integer less than or equal to 2m+1, 
and 
R is independently H, alkyl, hydroxyalkyl, or 
monosaccharide. 
26. The method of claim 2 wherein the carboxyalkyl is 
CH(21 OR or OCH(c21-OR where 
n is a positive integer from 1 to 10; 
y is zero or a positive integer less than (2n+1)-q), 
q is zero or a positive integer less than or equal to 2n+1, 
R is (CH2)CO.R., (CH),CONHR or 
(CH2)CONCR), where 
n is a positive integer from 1 to 10, 
R is independently H, alkyl, hydroxyalkyl, monosac 
charide, Con-w)Hom+1)-2O.O. O2CCon whic(2m+ 
1)-2w)OO or N(R)OCCH2-12O, O, 
where m is a positive integer from 1 to 10, 
w is Zero or a mositive integer less than or equal to m, 
Z is Zero or a positive integer less than or equal to 
((2m+1)-2w), 
R is H, alkyl, hydroxyalkyl, or CHOR, 
where 
m is a positive integer from 1 to 10, 
Z is zero or a positive integer less than ((2m+1)-r), 
r is zero or a Dositive integer less than or equal to 
2m+1, and R is independently H, alkyl, hydroxy 
alkyl, or monosaccharide. 
27. A method for synthesizing a metal complex of 4,5- 
diethyl-10,23-dimethyl-9,24-bis( 3-hydroxypropyl)-16,17 
(3-hydroxypropyloxy)- 13.20,25,26,27-pentaaza pentacyclo 
(20.2.1.13.18.0°]heptacosa 
1,3,5,7,9,11(27),12,14(19), 15,17.20,22(25), 23-tridecaene, 
the method comprising: 
mixing 4,5-diethyl-10,23-dimethyl-9,24-bis( 3-hydrox 
ypropyl)-16, 17-bis(3-hydroxypropyloxy)- 13,20,25,26, 
27-pentaazapentacyclo[20.2.1.1.1.0'']hepta 
cosa-3,5,8,10,12,14(19), 15,1720, 22.24-undecaene, a 
trivalent metal cation selected from the group consist 
ing of Mnt, Co, Ni's, Fets, Ho", Ce", Y-3, Int, 
Pr", Nd, Smt, Eut, Gd, Tb, Dy"3, Er, Tm", 
Yb", Lu, La", and U", a Brinsted base and an 
oxidant selected from the group consisting of air, 
oxygen, platinum oxide and 2,3-dichloro-5,6-dicyano 




3,5,8,10,12,14(19), 15,1720,22,24-undecaene; and stir 
ring at ambient temperature or heating the mixture at 













4,5-diethyl-10,23-dimethyl-9,24-bis ( 3-hydroxypro 
pyl)-16,17-(3-hydroxypropyloxy)- 13,20,25,26,27 
pentaazapentacyclo[20.2.1.1.1'0'''heptacosa 
1,3,5,7,9,11(27), 12, 14(19), 15,1720,22(25),23 
tridecaene. 
28. The method of claim 27 wherein the Brinsted base is 
triethylamine. 
29. The method of claim 27 wherein the oxidant is air and 
the air is saturating the organic solvent. 
30. The method of claim 27 wherein the stirring or heating 
at reflux step is stirring or heating at reflux the mixture for 
at least 24 hours. 
31. The method of claim 27 wherein the organic solvent 
comprises methanol and chloroform. 
32. The method of claim 27 wherein the organic solvent 
comprises methanol and benzene. 
33. The method of claim 27 wherein the organic solvent 
comprises methanol and dimethylformamide. 
34. The method of claim 1 wherein the metal cation is a 
trivalent cation selected from the group consisting of Mn", 
Co-3, Nit-3, Fe", Hot, Ce", Y+3, Int3, Pr!3, Nd", Sm', 
Eu, Gd, Tb, Dy", Er", Tm, Yb", Lu", La", and 
U+3. 
35. The method of claim 1 wherein the metal cation is a 
divalent cation selected from the group consisting of Ca', 
Mn, Co, Ni, Zn, Cd?, Hg, Sm'?, and UO'?. 
36. The method of claim 1 wherein the organic solvent 
comprises methanol. 
37. The method of claim 27 wherein the organic solvent 
comprises methanol. 
38. The method of claim 2 where R is hydroxyalkyl, R, 
R and R are alkyl; and Rs is oxyalkyl. 
39. The method of claim38 where the hydroxyalkyl of R 
is CHCHCH-OH, the alkyl of R and R is CHCH, the 
alkyl of R is CH, and the oxyalkyl of Rs is 
O(CHCHO)CHCHOR, where R is H or CH. 
40. The method of claim 39 where R is CH. 
41. The method of claim 40 where the metal cation is Lu 
(III) or Gd (III). 




1,3,5,7,9,11(27), 12, 14(19), 15, 17.20,22(25), 23-tridecaene, 
the method comprising: 




24-undecaene, a metal cation, a Brinsted base and an 
oxidant selected from the group consisting of air, 
oxygen, platinum oxide and 2,3-dichloro-5,6-dicyano 




6.18,11.0 '' heptacosa-3,5,8,10,12,14,16,18,2022, 
24-undecaene; and 
stirring at ambient temperature or heating the mixture at 
reflux for at least two hours to form a metal complex of 
4,5-diethyl-10,23-dimethyl-9,24-bis (3-hydroxypro 
pyl)- 16, 17-bis(2-2-(2-methoxyethoxy)ethoxyl 
ethoxy- 13,20,25,26,27-pentaazapentacyclo 
(20.2.1.1.1.0', heptacosa-1,3,5,7,9,11(27), 
12,14 (19), 15,17.20,22(25).2 3-tridecaene. 




44. The method of claim 42 wherein the oxidant is air and Co", Ni3, Fe", Ho", Ce", Y-3, In, Pr'3, Nd", Sm", 
the air is saturating the organic solvent. Eu", Gd'3, Tb", Dy", Ert, Tm", Yb", Lu", La", and 
45. The method of claim 42 wherein the organic solvent U" or a divalent cation selected from the group consisting 
consists of methanol and chloroform, methanol and benzene, of Cat?, Mn, Co, Ni, Zn, Cd?, Hg, Sm" and 
methanol and dimethylformamide, or methanol. 5 UO. 
46. The method of claim 42 wherein the metal cation is a 
trivalent cation selected from the group consisting of Mn", ck k k k cK 
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